

BCG vaccine

Section

Recommendations for all immunization programmes
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against tuberculosis

Japanese encephalitis vaccine

Section

Recommendations for certain regions
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Medicines for COVID-19

Section

Medicines for COVID-19
Refer to WHO living guidelines

Indications

COVID-19

Abacavir

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 300 mg tablet (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + lamivudine

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + lamivudine + lopinavir + ritonavir

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abemaciclib

Section

Targeted therapies

Indications

Therapeutic equivalent to palbociclib for

Other specified malignant neoplasms of breast

Abiraterone

Section

Hormones and antihormones

Oral > Solid: 250 mg; 500 mg

Indications

Malignant neoplasms of prostate

Acamprosate calcium

Section

Medicines for alcohol use disorders

Oral > Solid > tablet: 333 mg

Indications

Disorders due to use of alcohol

Acetazolamide

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Oral > Solid: 250 mg

Indications

Primary open-angle glaucoma

Acetic acid

Section

Ear, nose and throat medicines [c]

Local > Otological > drops: 2% in alcohol

Indications

Infectious diseases of external ear

Acetylcysteine

Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule

Oral > Liquid: 10%; 20%

Indications

Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

Acute or subacute hepatic failure

Acetylsalicylic acid

Section

Antimigraine medicines > For treatment of acute attack

Oral > Solid: 300 to 500 mg

Anti-platelet medicines

Oral > Solid: 100 mg

Medicines for juvenile joint diseases

Oral > Solid: 100 to 500 mg

Local > Rectal > Suppository: 50 to 150 mg

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

Oral > Solid: 100 to 500 mg

Local > Rectal > Suppository: 50 to 150 mg

Indications

Migraine

Acute myocardial infarction

Cerebral ischaemic stroke

Acute rheumatic fever without mention of heart involvement

Mucocutaneous lymph node syndrome

Juvenile idiopathic arthritis

Pain

Acetylsalicylic acid + atorvastatin + ramipril

Section

Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease

Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg

Indications

Atherosclerotic chronic arterial occlusive disease

Chronic ischaemic heart disease

Cerebral ischaemic stroke

Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide

Section

Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease

Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg

Indications

Atherosclerotic chronic arterial occlusive disease

Chronic ischaemic heart disease

Cerebral ischaemic stroke

Aciclovir

Section

Antiherpes medicines

Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)

Oral > Liquid: 200 mg per 5 mL

Oral > Solid: 200 mg tablet

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Ointment: 3% w/w

Indications

Zoster

Varicella

Herpes simplex infections

Herpes simplex keratitis

Aclidinium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to tiotropium bromide for

Chronic obstructive pulmonary disease

Activated charcoal

Section

Antidotes and other substances used in poisonings > Non-specific

Oral > Other: powder

Indications

Unspecified injury, poisoning or certain other consequences of external causes

Adalimumab

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Medicines for juvenile joint diseases

Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

Axial spondyloarthritis

Crohn disease site

Rheumatoid arthritis

Juvenile idiopathic arthritis

Afatinib

Section

Targeted therapies

Indications

Therapeutic equivalent to erlotinib for

Other specified malignant neoplasms of bronchus or lung

Albendazole

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 400 mg (chewable, scored)	<ul style="list-style-type: none">EchinococcosisEnterobiasisTrichuriasisHookworm diseasesCysticercosisAscariasis
Cysticidal medicines Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)	<ul style="list-style-type: none">Other specified echinococcosisCysticercosis of central nervous system
Antifilarials Oral > Solid > tablet: 400 mg (chewable, scored)	<ul style="list-style-type: none">Lymphatic filariasis

Alcohol based hand rub

Section	Indications
Disinfectants Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol	<ul style="list-style-type: none">Denatured alcohol

Alcuronium

Section	Indications
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)	<ul style="list-style-type: none">Muscle relaxants

Alfacalcidol

Section	Indications
Medicines for endocrine disorders Oral > Liquid: 2 µg per mL Oral > Solid > capsule: 0.25 µg; 1 µg	<ul style="list-style-type: none">Chronic kidney disease, stage unspecifiedDisorders of vitamin D metabolism or transport

All-trans retinoic acid

Section	Indications
Targeted therapies Oral > Solid: 10 mg capsule	<ul style="list-style-type: none">Acute myeloid leukaemia with recurrent genetic abnormalities

Allopurinol

Section

Medicines used to treat gout

Oral > Solid: 100 mg

Supportive medicines

Oral > Solid: 100 mg; 300 mg

Indications

Gout

Tumour lysis syndrome

Alteplase

Section

Thrombolytic medicines

Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection

Indications

Cerebral ischaemic stroke

Amidotrizoate

Section

Diagnostic agents > Radiocontrast media

Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)

Indications

Amidotrizoate

Amikacin

Section

Ophthalmological preparations > Anti-infective agents

Antituberculosis medicines

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Access group antibiotics

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

Therapeutic equivalent to gentamicin for

Other specified conjunctivitis

Therapeutic equivalent to gentamicin for

Infectious blepharitis

Multi-drug resistant Mycobacterium tuberculosis

First choice

Neutropenia (high-risk)

co-prescribed with cefotaxime

Inflammatory and other diseases of prostate (severe)

co-prescribed with cefotaxime

Acute pyelonephritis (severe)

co-prescribed with ceftriaxone

Inflammatory and other diseases of prostate (severe)

co-prescribed with ceftriaxone

Acute pyelonephritis (severe)

Second choice

co-prescribed with cloxacillin

Sepsis without septic shock

Amiloride

Section

Diuretics

Oral > Solid: 5 mg (hydrochloride)

Indications

Oedema

Ascites

Amiodarone

Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)

Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)

Indications

Cardiac arrhythmia

Amitriptyline

Section

Medicines for other common symptoms in palliative care

Oral > Solid: 25 mg; 10 mg; 75 mg

Medicines for depressive disorders

Oral > Solid: 25 mg; 75 mg

Indications

Palliative care

Depressive disorders

Amlodipine

Section

Antihypertensive medicines

Oral > Solid: 5 mg (as maleate, mesylate or besylate)

Indications

Essential hypertension

Amodiaquine

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Amodiaquine + sulfadoxine + pyrimethamine

Section

Antimalarial medicines > For chemoprevention

Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package

Indications

Malaria

Amoxicillin

Section

Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid

Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection

Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

Indications

First choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Acute malnutrition in infants, children or adolescents (uncomplicated) [children]

Acute malnutrition in infants, children or adolescents (complicated) [children]

Acute pharyngitis

Chronic obstructive pulmonary disease with acute exacerbation

Periapical abscess without sinus

Acute otitis media

Acute sinusitis

co-prescribed with gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with gentamicin

Sepsis without septic shock

Second choice

Bacterial meningitis

Other indications

Infectious cystitis

Bacterial infection of unspecified site

Amoxicillin + clavulanic acid

Section

Access group antibiotics

Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection

Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid

Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Antituberculosis medicines

Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

First choice

Peritoneal abscess (mild-moderate)

Neutropenia (low-risk)

Other specified pneumonia (Hospital-acquired pneumonia)

Infectious cystitis

Chronic obstructive pulmonary disease with acute exacerbation

Peritonitis (mild-moderate)

Acute sinusitis

Bacterial cellulitis, erysipelas or lymphangitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choice

Osteomyelitis or osteitis

Acute otitis media

Other specified prophylactic measures

Bacterial infection of joint

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

co-prescribed with clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

Other indications

Bacterial infection of unspecified site

Multi-drug resistant Mycobacterium tuberculosis

Amphotericin B

Section

Antifungal medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

Antileishmaniasis medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

Indications

Blastomycosis

Cryptococcosis

Candidosis

Coccidioidomycosis

Histoplasmosis

Sporotrichosis

Aspergillosis

Visceral leishmaniasis

Ampicillin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension

Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

co-prescribed with gentamicin

Peritoneal abscess (severe)

co-prescribed with gentamicin

Sepsis without septic shock

co-prescribed with gentamicin

Peritoneal abscess (mild-moderate)

co-prescribed with gentamicin

Peritonitis (severe)

co-prescribed with gentamicin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with gentamicin

Peritonitis (mild-moderate)

co-prescribed with gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

Anakinra

Section

Medicines for juvenile joint diseases
Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe

Indications

Juvenile systemic arthritis

Anastrozole

Section

Hormones and antihormones
Oral > Solid: 1 mg tablet

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Anidulafungin

Section

Antifungal medicines

Indications

Therapeutic equivalent to micafungin for

Systemic or invasive candidosis

Ansuvimab

Section

Medicines for Ebola virus disease
Parenteral > General injections > IV: 400 mg powder for injection

Indications

Ebola virus disease

Anti-D immunoglobulin

Section

Human immunoglobulins
Parenteral > General injections > IV: 250 µg in single-dose vial
Parenteral > General injections > IM: 250 µg in single-dose vial

Indications

Maternal care for red cell antibodies

Rh incompatibility reaction

Anti-rabies immunoglobulin

Section

Human immunoglobulins
Parenteral > General injections > IM: 150 IU per mL in vial
Parenteral > Locoregional injections > Other: 150 IU per mL in vial

Indications

Rabies

Anti-rabies virus monoclonal antibodies

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies
Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)

Indications

Rabies

Anti-tetanus immunoglobulin

Section

Human immunoglobulins
Parenteral > General injections > IM: 500 IU in vial

Indications

Tetanus

Antirabies hyperimmune serum

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies
Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule

Indications

Rabies

Antivenom immunoglobulin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies
Parenteral > General injections > IV:

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Antivenom sera

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies
Parenteral > General injections > IV:

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Apixaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for

Venous thromboembolism

Therapeutic equivalent to [dabigatran](#) for

Other specified atrial fibrillation

Aprepitant

Section

Antiemetic medicines

Oral > Liquid: 125 mg powder for oral suspension (in sachet)

Oral > Solid: 80 mg; 125 mg; 165 mg

Indications

Nausea or vomiting

Aripiprazole

Section

Medicines for psychotic disorders

Indications

Therapeutic equivalent to risperidone for

Schizophrenia or other primary psychotic disorders

Arsenic trioxide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Artemether

Section

Antimalarial medicines > For curative treatment

Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artemether + lumefantrine

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artesunate

Section

Antimalarial medicines > For curative treatment

Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution

Oral > Solid: 50 mg tablet

Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artesunate + amodiaquine

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Artesunate + mefloquine

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Artesunate + pyronaridine tetraphosphate

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Ascorbic acid

Section

Vitamins and minerals

Oral > Solid: 50 mg

Indications

Scurvy

Asparaginase

Section

Cytotoxic medicines

Powder for injection: 10 000 IU in vial.

Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Atazanavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atazanavir + ritonavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atenolol

Section

Antianginal medicines

Oral > Solid: 50 mg; 100 mg

Antihypertensive medicines

Oral > Solid: 50 mg; 100 mg

Indications

Angina pectoris

Essential hypertension

Therapeutic equivalent to bisoprolol for

Essential hypertension

Atezolizumab

Section

Immunomodulators

Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab for

Other specified malignant neoplasms of bronchus or lung

Atoltivimab + maftivimab + odesivimab

Section

Medicines for Ebola virus disease

Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

Indications

Ebola virus disease

Atorvastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to simvastatin for

Mixed hyperlipidaemia

Therapeutic equivalent to simvastatin for

Coronary atherosclerosis

Atorvastatin + perindopril + amlodipine

Section

Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease

Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg

Indications

Chronic ischaemic heart disease

Atherosclerotic chronic arterial occlusive disease

Cerebral ischaemic stroke

Atracurium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 10 mg per mL (besylate)

Indications

Muscle relaxants

Therapeutic equivalent to **vecuronium** for

Muscle relaxants

Atropine

Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)

Preoperative medication and sedation for short-term procedures

Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)

Diagnostic agents > Ophthalmic medicines

Ophthalmological preparations > Mydriatics

Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)

Indications

Exposure to or harmful effects of undetermined intent of pesticides

Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics

Therapeutic equivalent to **tropicamide** for

Cycloplegic drug

Anterior uveitis

Axicabtagene ciloleucel

Section

Antineoplastics and supportive medicines

Cell suspension for infusion: 2×10^6 anti-CD19 CAR-positive viable T-cells per kg of body weight.

Indications

Diffuse large B-cell lymphomas

Azacitidine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

Indications

Myeloid leukaemia

Azathioprine

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)

Oral > Liquid: 10 mg per mL

Oral > Solid > tablet: 25 mg; 50 mg (scored)

Oral > Solid > tablet: 50 mg (scored)

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid > tablet: 50 mg (scored)

Indications

Failure or rejection of transplanted organs or tissues

Relapsing-remitting multiple sclerosis

Rheumatoid arthritis, serology unspecified

Psoriatic arthritis

Azithromycin

Section

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Solution (eye drops): 1.5% eye drops

Watch group antibiotics

Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

Trachoma

First choice

Chlamydia trachomatis

Typhoid fever

Yaws

Paratyphoid fever

Cholera

Cholera [children]

Trachoma

co-prescribed with ceftriaxone

Gonococcal infection

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with cefixime

Gonococcal infection

Aztreonam

Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified bacterial diseases

Barium sulfate

Section

Diagnostic agents > Radiocontrast media

Oral > Liquid: Aqueous suspension

Indications

Barium sulfate with suspending agents

Beclometasone

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)

Indications

Therapeutic equivalent to budesonide for

Asthma

Asthma

Beclometasone + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide + formoterol for

Asthma

Bedaquiline

Section

Antituberculosis medicines

Oral > Solid: 100 mg tablet; 20 mg tablet

Indications

Multi-drug resistant Mycobacterium tuberculosis

Bendamustine

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

Benzathine benzylpenicillin

Section

Access group antibiotics

Parenteral > General injections > IM: 1.2 million IU in vial (\approx 900 mg) powder for injection; 2.4 million IU in vial (\approx 1.8 g) powder for injection

Indications

First choice

Syphilis

Congenital syphilis [children]

Other indications

Bacterial infection of unspecified site

Benznidazole

Section

American trypanosomiasis

Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg

Indications

Chagas disease

Benzoic acid + salicylic acid

Section

Dermatological medicines > Antifungal medicines

Local > Topical > Cream: 6% + 3%

Local > Topical > Ointment: 6% + 3%

Indications

Fungal infection of the skin

Benzoyl peroxide

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Cream: 5%

Local > Topical > Lotion: 5%

Indications

Acne

Benzyl benzoate

Section

Dermatological medicines > Scabicides and pediculicides

Local > Topical > Lotion: 25%

Indications

Pthiriasis

Pediculosis corporis

Pediculosis capitis

Scabies

Benzylpenicillin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Indications

First choice

Congenital syphilis [children]

Syphilis

co-prescribed with gentamicin

Sepsis without septic shock

co-prescribed with gentamicin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

Betamethasone

Section

Dermatological medicines > Anti-inflammatory and antipruritic medicines

Local > Topical > Cream: 0.1% (as valerate)

Local > Topical > Ointment: 0.1% (as valerate)

Indications

Pruritus due to skin disorder

Psoriasis of unspecified type

Dermatitis or eczema

Lichen planus

Bevacizumab

Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

Indications

Age related macular degeneration

Bicalutamide

Section

Hormones and antihormones

Oral > Solid: 50 mg

Indications

Malignant neoplasms of prostate

Binimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to trametinib for

Other specified melanoma of skin

Biperiden

Section

Medicines for parkinsonism

Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)

Oral > Solid: 2 mg tablet (hydrochloride)

Indications

Parkinson disease

Bisacodyl

Section

Laxatives

Indications

Therapeutic equivalent to senna for

Constipation

Bisoprolol

Section

Antianginal medicines

Oral > Solid: 1.25 mg; 5 mg

Medicines used in heart failure

Oral > Solid: 1.25 mg; 5 mg

Antihypertensive medicines

Oral > Solid: 1.25 mg; 5 mg

Antiarrhythmic medicines

Oral > Solid: 1.25 mg; 5 mg

Indications

Angina pectoris

Heart failure

Essential hypertension

Cardiac arrhythmia

Bleomycin

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)

Indications

Germ cell tumour of testis

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of ill-defined or unspecified sites

Bortezomib

Section

Targeted therapies

Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

Indications

Plasma cell myeloma

Bromocriptine

Section

Antiseizure medicines

Oral > Solid: 2.5 mg; 5 mg

Medicines for disorders of the pituitary hormone system

Indications

Parkinson disease

Therapeutic equivalent to cabergoline for

Other specified benign neoplasm of endocrine glands

Budesonide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose

Ear, nose and throat medicines [c]

Local > Nasal > Spray: 100 µg per dose

Indications

Asthma

Allergic rhinitis

Budesonide + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose

Indications

Asthma

Budesonide + salmeterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide + formoterol for

Asthma

Bumetanide

Section

Medicines used in heart failure

Diuretics

Indications

Therapeutic equivalent to furosemide for

Heart failure

Therapeutic equivalent to furosemide for

Anuria or oliguria

Therapeutic equivalent to furosemide for

Oedema

Bupivacaine

Section

Local anaesthetics

Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution

Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)

Indications

Local anaesthetics

Buprenorphine

Section

Medicines for opioid use disorders

Indications

Therapeutic equivalent to methadone for

Opioid dependence

Bupropion

Section

Medicines for nicotine use disorders

Oral > Solid: 150 mg sustained-release (hydrochloride)

Indications

Nicotine dependence

C1 esterase inhibitor

Section

Plasma-derived medicines

Parenteral > General injections > IV: 500 IU in vial powder for injection

Indications

Hereditary angioedema

Cabergoline

Section

Medicines for disorders of the pituitary hormone system

Oral > Solid > tablet: 0.5 mg; 1 mg

Antiseizure medicines

Oral > Solid > tablet: 0.5 mg

Indications

Other specified benign neoplasm of endocrine glands

Parkinson disease

Caffeine citrate

Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)

Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)

Indications

Apnoea of newborn

Calamine

Section

Dermatological medicines > Anti-inflammatory and antipruritic medicines

Local > Topical > Lotion:

Indications

Pruritus

Calcipotriol

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Cream: 50 µg per mL (0.005%)

Local > Topical > Lotion: 50 µg per mL (0.005%)

Local > Topical > Ointment: 50 µg per mL (0.005%)

Indications

Psoriasis of unspecified type

Calcitriol

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Medicines for endocrine disorders

Oral > Solid > capsule: 0.25 µg; 0.5 µg

Indications

Therapeutic equivalent to calcipotriol for

Psoriasis of unspecified type

Chronic kidney disease, stage unspecified

Disorders of vitamin D metabolism or transport

Calcium

Section

Vitamins and minerals

Oral > Solid: 500 mg (elemental calcium)

Indications

Calcium deficiency

Calcium folinate (leucovorin calcium)

Section

Cytotoxic medicines

Oral > Solid: 15 mg tablet

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasm metastasis in large intestine

Malignant trophoblastic neoplasms of placenta

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of rectum

Malignant neoplasms of colon

Calcium gluconate

Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Vitamins and minerals

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

Hypermagnesaemia

Tetany due to acute calcium deficiency

Canagliflozin

Section

Oral hypoglycaemic agents

Indications

Therapeutic equivalent to empagliflozin for

Type 2 diabetes mellitus

Capecitabine

Section

Cytotoxic medicines

Oral > Solid > tablet: 150 mg; 500 mg

Indications

Other specified malignant neoplasms of breast

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

Malignant neoplasms of colon

Capreomycin

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Captopril

Section

Medicines used in heart failure

Oral > Solid: 25 mg

Indications

Heart failure

Carbachol

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Indications

Therapeutic equivalent to pilocarpine for

Acute angle closure with pupillary block

Therapeutic equivalent to pilocarpine for

Ocular hypertension

Therapeutic equivalent to pilocarpine for

Primary open-angle glaucoma

Carbamazepine

Section

Medicines for bipolar disorders

Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg

Antiseizure medicines

Oral > Liquid: 100 mg per 5 mL

Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)

Indications

Bipolar or related disorders

Epilepsy or seizures

Carbetocin

Section

Uterotonics

Parenteral > General injections > IV: 100 µg per mL (heat stable)

Indications

Postpartum haemorrhage

Carbimazole

Section

Thyroid hormones and antithyroid medicines

Indications

Therapeutic equivalent to methimazole for

Thyrotoxicosis

Carboplatin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

Other specified gliomas of brain

Other specified carcinomas of ovary

Retinoblastoma

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Malignant neoplasms of kidney, except renal pelvis

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of lip, oral cavity or pharynx

Malignant neoplasms of cervix uteri

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Carmellose

Section

Ophthalmological preparations

Indications

Therapeutic equivalent to hypromellose for

Keratoconjunctivitis sicca

Carvedilol

Section

Antianginal medicines

Indications

Therapeutic equivalent to bisoprolol for

Angina pectoris

Medicines used in heart failure

Therapeutic equivalent to bisoprolol for

Heart failure

Antihypertensive medicines

Therapeutic equivalent to bisoprolol for

Essential hypertension

Antiarrhythmic medicines

Therapeutic equivalent to bisoprolol for

Cardiac arrhythmia

Caspofungin

Section

Antifungal medicines

Indications

Therapeutic equivalent to micafungin for

Systemic or invasive candidosis

Cefalexin

Section

Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid: 250 mg (as monohydrate)

Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)

Oral > Solid > dispersible tablet: 125 mg; 250 mg

Indications

First choice

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Acute pharyngitis

Chronic obstructive pulmonary disease with acute exacerbation

Other indications

Bacterial infection of unspecified site

Cefazolin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

First choice

Other specified prophylactic measures

co-prescribed with metronidazole

Other specified prophylactic measures

Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

Other indications

Surgical site infection

Cefepime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

Other specified bacterial diseases

Cefiderocol

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Cefixime

Section

Watch group antibiotics

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with azithromycin

Gonococcal infection

Cefotaxime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

Other specified pneumonia (Hospital-acquired pneumonia)

Bacterial meningitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with amikacin

Inflammatory and other diseases of prostate (severe)

co-prescribed with amikacin

Acute pyelonephritis (severe)

co-prescribed with clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with metronidazole

Peritonitis (severe)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

co-prescribed with metronidazole

Peritoneal abscess (severe)

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Sepsis without septic shock

Other indications

Bacterial infection of unspecified site

Ceftaroline

Section

Reserve group antibiotics

Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

Other specified bacterial diseases

Ceftazidime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

First choice

co-prescribed with [vancomycin](#)

[Endophthalmitis](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

Ceftazidime + avibactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)

[Carbapenem resistant Enterobacterales](#)

Ceftolozane + tazobactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)

Ceftriaxone

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Indications

First choice

[Typhoid fever](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

[Paratyphoid fever](#)

[Other specified pneumonia \(Hospital-acquired pneumonia\)](#)

[Bacterial meningitis](#)

co-prescribed with [amikacin](#)

[Acute pyelonephritis \(severe\)](#)

co-prescribed with [amikacin](#)

[Inflammatory and other diseases of prostate \(severe\)](#)

co-prescribed with [azithromycin](#)

[Gonococcal infection](#)

co-prescribed with [clarithromycin](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

co-prescribed with metronidazole

Necrotising fasciitis

co-prescribed with metronidazole

Peritonitis (mild-moderate)

co-prescribed with metronidazole

Peritonitis (severe)

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

co-prescribed with metronidazole

Peritoneal abscess (severe)

co-prescribed with vancomycin

Endophthalmitis

Second choice

Bacterial infection of joint

Osteomyelitis or osteitis

Infectious gastroenteritis or colitis without specification of infectious agent

Sepsis without septic shock

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Other indications

Bacterial infection of unspecified site

Cefuroxime

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

Other specified prophylactic measures

Cemiplimab

Section

Immunomodulators

Indications

Therapeutic equivalent to pembrolizumab for

Other specified malignant neoplasms of bronchus or lung

Certolizumab pegol

Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for

[Axial spondyloarthritis](#)

Therapeutic equivalent to [adalimumab](#) for

[Crohn disease site](#)

Therapeutic equivalent to [adalimumab](#) for

[Rheumatoid arthritis](#)

Therapeutic equivalent to [adalimumab](#) for

[Juvenile idiopathic arthritis](#)

Cetirizine

Section

Antiallergics and medicines used in anaphylaxis

Indications

Therapeutic equivalent to [loratadine](#) for

[Allergic or hypersensitivity conditions of unspecified type](#)

Chlorambucil

Section

Cytotoxic medicines

Oral > Solid: 2 mg tablet

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

[Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)

Chloramphenicol

Section

[Access group antibiotics](#)

Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)

Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection

Oral > Liquid: 150 mg per 5 mL (as palmitate)

Oral > Solid: 250 mg capsule

Indications

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Chlorhexidine

Section

Medicines administered to the neonate [c]

Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)

Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)

Antiseptics

Local > Topical > Solution: 5% (digluconate) for dilution

Indications

Omphalitis of newborn

Chlorhexidine

Chlorine base compound

Section

Disinfectants

Local > Topical > Powder: 0.1% available chlorine for solution

Local > Topical > Liquid: 0.1% available chlorine for solution

Local > Topical > Solid: 0.1% available chlorine for solution

Indications

Disinfectant, not elsewhere classified

Chloroquine

Section

Antimalarial medicines > For chemoprevention

Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)

Oral > Solid: 150 mg tablet (as phosphate or sulfate)

Antimalarial medicines > For curative treatment

Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)

Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)

Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Malaria due to Plasmodium ovale

Malaria due to Plasmodium malariae

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Rheumatoid arthritis

Chlorothiazide

Section

Antihypertensive medicines

Medicines used in heart failure

Indications

Therapeutic equivalent to hydrochlorothiazide for

Essential hypertension

Therapeutic equivalent to hydrochlorothiazide for

Heart failure

Chloroxylonol

Section

Disinfectants

Local > Topical > Solution: 4.8%

Indications

Phenol disinfectant, not elsewhere classified

Chlorpromazine

Section

Medicines for psychotic disorders

Oral > Liquid: 25 mg per 5 mL (hydrochloride)

Oral > Solid: 100 mg (hydrochloride)

Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)

Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)

Indications

Therapeutic equivalent to haloperidol for

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

Chlortalidone

Section

Antihypertensive medicines

Medicines used in heart failure

Indications

Therapeutic equivalent to hydrochlorothiazide for

Essential hypertension

Therapeutic equivalent to hydrochlorothiazide for

Heart failure

Chlortetracycline

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to tetracycline for

Other specified conjunctivitis

Therapeutic equivalent to tetracycline for

Infectious keratitis

Therapeutic equivalent to tetracycline for

Infectious blepharitis

Therapeutic equivalent to tetracycline for

Trachoma

Cholera vaccine

Section

Recommendations for some high-risk populations

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against cholera alone

Ciclesonide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide for

Asthma

Ciclosporin

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection

Oral > Liquid: 100 mg per mL

Oral > Solid > capsule: 25 mg

Indications

Failure or rejection of transplanted organs or tissues

Cimetidine

Section

Antiulcer medicines

Oral > Solid: 200 mg

Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule

Indications

Peptic ulcer, site unspecified

Gastro-oesophageal reflux disease

Ciprofloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 2 mg per mL (as hyclate)

Oral > Liquid: 250 mg per 5 mL (anhydrous)

Oral > Solid: 250 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Ear, nose and throat medicines [c]

Local > Otological > drops: 0.3% (as hydrochloride)

Indications

First choice

Neutropenia (low-risk)

Inflammatory and other diseases of prostate (mild to moderate)

Typhoid fever

Paratyphoid fever

Infectious gastroenteritis or colitis without specification of infectious agent

Acute pyelonephritis (mild to moderate)

Second choice

Cholera

Cholera [children]

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

Other indications

Bacterial infection of unspecified site

Infectious diseases of external ear

Cisplatin

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection

Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Germ cell tumour of testis

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of lip, oral cavity or pharynx

Malignant neoplasms of cervix uteri

Cladribine

Section

Medicines for multiple sclerosis

Oral > Solid > tablet: 10 mg

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

Indications

Multiple sclerosis

Langerhans cell histiocytosis

Clarithromycin

Section

Watch group antibiotics

Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Oral > Solid > dosage form: 500 mg; 250 mg

Oral > Solid > dosage form: 500 mg

Indications

First choice

co-prescribed with cefotaxime

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with ceftriaxone

Bacterial pneumonia (Community-acquired pneumonia - severe)

Second choice

Acute pharyngitis

co-prescribed with amoxicillin + clavulanic acid

Bacterial pneumonia (Community-acquired pneumonia - severe)

Other indications

Helicobacter pylori associated gastric ulcer

Clindamycin

Section

Access group antibiotics

Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride) capsule

Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection

Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)

Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride)

Indications

First choice

co-prescribed with piperacillin + tazobactam

Necrotising fasciitis

Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

Other indications

Bacterial infection of unspecified site

Clofazimine

Section

Antituberculosis medicines
Oral > Solid: 100 mg; 50 mg

Antileprosy medicines
Oral > Solid: 100 mg; 50 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Leprosy

Clomifene

Section

Ovulation inducers
Oral > Solid: 50 mg (citrate)

Indications

Female infertility without specification whether primary or secondary

Clomipramine

Section

Medicines for obsessive compulsive disorders
Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)

Indications

Obsessive-compulsive disorder

Clonazepam

Section

Antiseizure medicines
Oral > Solid: 500 µg

Indications

Generalised myoclonic seizure

Clopidogrel

Section

Anti-platelet medicines
Oral > Solid: 75 mg; 300 mg

Indications

Acute ischaemic heart disease

Presence of coronary angioplasty implant or graft

Clotrimazole

Section

Antifungal medicines
Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet

Indications

Vulvovaginal candidosis

Cloxacillin

Section

Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid

Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection

Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

Indications

First choice

Bacterial infection of joint

Osteomyelitis or osteitis

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

co-prescribed with amikacin

Sepsis without septic shock

Other indications

Bacterial infection of unspecified site

Clozapine

Section

Medicines for psychotic disorders

Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg

Indications

Schizophrenia or other primary psychotic disorders

Coagulation factor IX

Section

Blood coagulation factors

Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

Coagulation defects, purpura or other haemorrhagic or related conditions

Haemophilia B

Coagulation factor IX complex

Section

Blood coagulation factors

Indications

Therapeutic equivalent to coagulation factor IX for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to coagulation factor IX for

Haemophilia B

Coagulation factor VIII

Section

Blood coagulation factors

Parenteral > General injections > IV: 250 IU in vial powder for injection;
500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

Haemophilia A

Coal tar

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Solution: 5%

Indications

Psoriasis of unspecified type

Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Cobimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to trametinib for

Other specified melanoma of skin

Codeine

Section

Opioid analgesics

Oral > Solid: 30 mg tablet (codeine phosphate)

Antitussives

Oral > Solid: 10 mg tablet (codeine phosphate)

Medicines for diarrhoea

Oral > Solid: 30 mg tablet (codeine phosphate)

Indications

Pain

Cough

Diarrhoea

Colchicine

Section

Medicines used to treat gout

Oral > Solid: 0.5 mg

Indications

Gout

Colecalciferol

Section

Vitamins and minerals

Oral > Liquid: 400 IU per mL

Oral > Solid: 400 IU; 1000 IU

Indications

Calcium deficiency

Vitamin D deficiency

Therapeutic equivalent to ergocalciferol for

Vitamin D deficiency

Therapeutic equivalent to ergocalciferol for

Calcium deficiency

Colistin (injection)

Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Compound sodium lactate solution

Section

Solutions correcting water, electrolyte and acid-base disturbances >

Parenteral

Parenteral > General injections > IV: injectable solution

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Hypovolaemic shock

Condoms

Section

Barrier methods

-

Indications

Contact with health services for contraceptive management

Copper-containing intrauterine device

Section

Intrauterine devices

-

Indications

Contact with health services for insertion of contraceptive device

Crizotinib

Section

Targeted therapies

Oral > Solid: 200 mg; 250 mg

Oral > Solid > capsule: 200 mg; 250 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Anaplastic large cell lymphoma, ALK-positive

Cryoprecipitate (not pathogen-reduced)

Section

Blood and blood components

Indications

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Haemophilia A

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Von Willebrand disease

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Obstetric haemorrhage

Cryoprecipitate (pathogen-reduced)

Section

Blood and blood components

Injection: frozen liquid in bag or lyophilized powder in vial containing:

> 50 IU Factor VIII

> 100 IU vWF

> 140 mg clottable fibrinogen per unit

Indications

Haemophilia A

Coagulation defects, purpura or other haemorrhagic or related conditions

Von Willebrand disease

Obstetric haemorrhage

Cyanocobalamin

Section

Antianaemia medicines

.

Indications

Anaemias or other erythrocyte disorders

Cyclizine

Section

Medicines for other common symptoms in palliative care

Oral > Solid: 50 mg tablet

Parenteral > General injections > unspecified: 50 mg per mL

Indications

Palliative care

Cyclopentolate

Section

Diagnostic agents > Ophthalmic medicines

Ophthalmological preparations > Mydriatics

Indications

Therapeutic equivalent to tropicamide for

Cycloplegic drug

Therapeutic equivalent to atropine for

Anterior uveitis

Cyclophosphamide

Section

Cytotoxic medicines

Oral > Solid: 25 mg tablet

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Oral > Solid > dosage form: 25 mg; 50 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified malignant neoplasms of breast

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Malignant neoplasms of breast

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Rhabdomyosarcoma primary site

Hodgkin lymphoma

Diffuse large B-cell lymphomas

Plasma cell myeloma

Other specified gliomas of brain

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Cycloserine

Section

Antituberculosis medicines
Oral > Solid: 250 mg; 125 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Cytarabine

Section

Cytotoxic medicines
Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Dabigatran

Section

Medicines affecting coagulation
Oral > Solid: 110 mg; 150 mg

Indications

Venous thromboembolism

Other specified atrial fibrillation

Dabrafenib

Section

Targeted therapies
Oral > Solid: 50 mg; 75 mg

Indications

Other specified melanoma of skin

Dacarbazine

Section

Cytotoxic medicines
Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

Indications

Hodgkin lymphoma

Daclatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid > tablet: 30 mg (as hydrochloride); 60 mg (as hydrochloride)

Indications

Chronic hepatitis C

Daclatasvir + sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid > tablet: 60 mg + 400 mg

Indications

Chronic hepatitis C

Dactinomycin

Section

Cytotoxic medicines
Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Malignant trophoblastic neoplasms of placenta

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Ewing sarcoma of bone and articular cartilage of unspecified sites

Dalteparin

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to enoxaparin for

Acute ischaemic heart disease

Therapeutic equivalent to enoxaparin for

Venous thromboembolism

Dapagliflozin

Section

Oral hypoglycaemic agents

Indications

Therapeutic equivalent to empagliflozin for

Type 2 diabetes mellitus

Dapsone

Section

Antileprosy medicines

Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

Indications

Leprosy

Daptomycin

Section

Reserve group antibiotics

Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

Other specified bacterial diseases

Daratumumab

Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

Indications

Plasma cell myeloma

Darbepoetin alfa

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Darunavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dasabuvir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 250 mg tablet

Indications

Chronic hepatitis C

Dasatinib

Section

Targeted therapies

Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

Indications

Chronic myeloid leukaemia, not elsewhere classified

Daunorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Deferasirox

Section

Other medicines for haemoglobinopathies

Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg

Oral > Solid > tablet: 90 mg; 180 mg; 360 mg

Indications

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias

Therapeutic equivalent to deferoxamine for

Thalassaemias

Deferiprone

Section

Other medicines for haemoglobinopathies

Indications

Therapeutic equivalent to deferasirox for

Other specified sickle cell disorders or other haemoglobinopathies

Therapeutic equivalent to deferasirox for

Thalassaemias

Deferoxamine

Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Other medicines for haemoglobinopathies

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Indications

Harmful effects of drugs, medicaments or biological substances, not elsewhere classified

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias

Delafloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 300 mg lyophilized powder for injection

Oral > Solid: 450 mg

Indications

Methicillin resistant *Staphylococcus aureus*

Delamanid

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 25 mg

Oral > Solid > tablet: 50 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Dengue vaccine

Section

Recommendations for some high-risk populations

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Desmopressin

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)

Local > Nasal > Spray: 10 µg per dose (acetate)

Indications

Haemophilia A

Von Willebrand disease

Dexamethasone

Section

Other medicines administered to the mother

Parenteral > General injections > unspecified: 4 mg per mL
(dexamethasone phosphate (as sodium))

Hormones and antihormones

Oral > Solid: 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL
ampoule (as disodium phosphate salt)

Oral > Liquid: 2 mg per 5 mL

Oral > Solid: 2 mg; 4 mg

Antiallergics and medicines used in anaphylaxis

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL
ampoule (as disodium phosphate salt)

Medicines for other common symptoms in palliative care

Oral > Liquid: 2 mg per 5 mL

Oral > Solid: 2 mg; 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL
ampoule (as disodium phosphate salt)

Antiemetic medicines

Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL

Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL
ampoule (as disodium phosphate salt)

Indications

Respiratory distress syndrome of the newborn,
altered by maternal corticosteroid therapy

Plasma cell myeloma

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Allergic or hypersensitivity conditions of
unspecified type

Palliative care

Nausea or vomiting

Dextran 40

Section

Plasma substitutes

.

Indications

Hypovolaemia

Dextran 70

Section

Plasma substitutes

Parenteral > General injections > IV: 6% injectable solution

Indications

Hypovolaemia

Diaphragms

Section

Barrier methods

-

Indications

Contact with health services for contraceptive management

Diazepam

Section

Antiseizure medicines

Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system

Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube

Medicines for other common symptoms in palliative care

Oral > Liquid: 2 mg per 5 mL

Oral > Solid: 5 mg; 10 mg

Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system

Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube

Parenteral > General injections > unspecified: 5 mg per mL

Medicines for anxiety disorders

Oral > Solid: 5 mg (scored); 2 mg (scored)

Indications

Therapeutic equivalent to lorazepam for

Status epilepticus

Status epilepticus

Palliative care

Anxiety

Diazoxide

Section

Medicines for hypoglycaemia

Oral > Liquid: 50 mg per mL

Oral > Solid: 50 mg

Indications

Persistent hyperinsulinaemic hypoglycaemia of infancy

Didanosine

Section

[Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors](#)

Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution

Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Diethylcarbamazine

Section

[Antifilarials](#)

Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)

Indications

Lymphatic filariasis

Digitoxin

Section

[Medicines used in heart failure](#)

Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule

Oral > Solid: 50 µg; 100 µg

Indications

Heart failure

Digoxin

Section

[Antiarrhythmic medicines](#)

Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule

Oral > Liquid: 50 µg per mL

Oral > Solid: 62.5 µg; 250 µg

[Medicines used in heart failure](#)

Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule

Oral > Liquid: 50 µg per mL

Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg

Indications

Cardiac arrhythmia

Heart failure

Dihydroartemisinin + piperazine phosphate

Section

Antimalarial medicines > For curative treatment
Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Dihydroergocryptine mesylate

Section

Antiseizure medicines
Oral > Solid:

Indications

Parkinson disease

Diloxanide

Section

Antiamoebic and anti giardiasis medicines
Oral > Solid: 500 mg (furoate)

Indications

Amoebiasis

Dimercaprol

Section

Antidotes and other substances used in poisonings > Specific
Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Diphtheria antitoxin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies
Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial

Indications

Need for immunization against diphtheria alone

Diphtheria vaccine

Section

Recommendations for all immunization programmes
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against diphtheria alone

Diphtheria-pertussis-tetanus vaccine

Section

Recommendations for all immunization programmes
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against diphtheria-tetanus-pertussis, combined

Diphtheria-tetanus vaccine

Section

Recommendations for all immunization programmes
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against combinations of infectious diseases

Docetaxel

Section

Cytotoxic medicines
Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Malignant neoplasms of prostate

Unspecified malignant neoplasms of ill-defined or unspecified sites

Docusate sodium

Section

Medicines for other common symptoms in palliative care
Oral > Liquid: 50 mg per 5 mL oral liquid
Oral > Solid: 100 mg capsule

Indications

Palliative care

Dolasetron

Section

Medicines for other common symptoms in palliative care

Antiemetic medicines

Indications

Therapeutic equivalent to ondansetron for

Palliative care

Therapeutic equivalent to ondansetron for

Nausea or vomiting

Dolutegravir

Section

Antiretrovirals > Integrase inhibitors
Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dolutegravir + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Donepezil

Section

Medicines for diseases of the nervous system

Oral > Liquid: 1 mg per mL (hydrochloride)

Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)

Indications

Dementia due to Alzheimer disease

Dopamine

Section

Medicines used in heart failure

Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)

Indications

Heart failure

Cardiogenic shock

Doxorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Rhabdomyosarcoma primary site

Malignant neoplasms of breast

Hodgkin lymphoma

Diffuse large B-cell lymphomas

Plasma cell myeloma

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Anaplastic large cell lymphoma, ALK-negative

Other specified malignant neoplasms of breast

Anaplastic large cell lymphoma, ALK-positive

Ewing sarcoma of bone and articular cartilage of unspecified sites

Kaposi sarcoma of unspecified primary site

Doxorubicin (as pegylated liposomal)

Section

Cytotoxic medicines

Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Kaposi sarcoma of unspecified primary site

Doxycycline

Section

Access group antibiotics

Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)

Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)

Oral > Solid > dispersible tablet: 100 mg (as monohydrate)

Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)

Oral > Solid > dosage form: 100 mg (as hyclate)

Antimalarial medicines > For curative treatment

Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)

Antimalarial medicines > For chemoprevention

Oral > Solid: 100 mg (hydrochloride or hyclate)

Indications

First choice

Chlamydia trachomatis

Cholera

Second choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Chronic obstructive pulmonary disease with acute exacerbation

Cholera [children]

Other indications

Bacterial infection of unspecified site

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium falciparum

Durvalumab

Section

Immunomodulators

Parenteral > General injections > IV: 120 mg per 2.4 mL in vial; 500 mg per 10 mL in vial

Indications

Other specified malignant neoplasms of bronchus or lung

Edoxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to dabigatran for

Venous thromboembolism

Therapeutic equivalent to dabigatran for

Other specified atrial fibrillation

Efavirenz

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

Oral > Solid: 600 mg tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz + emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Eflornithine

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)

Indications

African trypanosomiasis

Elbasvir + grazoprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 50 mg + 100 mg

Indications

Chronic hepatitis C

Empagliflozin

Section

Oral hypoglycaemic agents

Oral > Solid: 10 mg; 25 mg

Indications

Type 2 diabetes mellitus

Emtricitabine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 10 mg per mL

Oral > Solid: 200 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 25 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Emtricitabine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Enalapril

Section

Antihypertensive medicines

Oral > Liquid: 1 mg per mL (as hydrogen maleate)

Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

Medicines used in heart failure

Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

Indications

Essential hypertension

Heart failure

Encorafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to [dabrafenib](#) for

Other specified melanoma of skin

Enoxaparin

Section

Medicines affecting coagulation

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

Indications

Acute ischaemic heart disease

Venous thromboembolism

Entecavir

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 0.05 mg per mL

Oral > Solid: 0.5 mg; 1 mg

Indications

Chronic hepatitis B

Enzalutamide

Section

Hormones and antihormones

Oral > Solid: 40 mg

Indications

Therapeutic equivalent to [abiraterone](#) for

Malignant neoplasms of prostate

Malignant neoplasms of prostate

Ephedrine

Section

Local anaesthetics

Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)

Indications

Cardiac complications of anaesthesia during labour or delivery

Epinephrine

Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)

Ophthalmological preparations > Mydriatics

Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)

Antiallergics and medicines used in anaphylaxis

Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)

Indications

Cardiac arrest

Primary open-angle glaucoma

Asthma

Chronic obstructive pulmonary disease

Anaphylaxis

Epoetin alfa

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Epoetin beta

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Epoetin theta

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Equine rabies immunoglobulin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial

Indications

Rabies

Eravacycline

Section

Reserve group antibiotics

Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

Carbapenem resistant Enterobacterales

Ergocalciferol

Section

Vitamins and minerals

Oral > Liquid: 250 µg per mL (10 000 IU per mL)

Oral > Solid: 1.25 mg (50 000 IU)

Indications

Therapeutic equivalent to [colecalciferol](#) for

Calcium deficiency

Therapeutic equivalent to [colecalciferol](#) for

Vitamin D deficiency

Vitamin D deficiency

Calcium deficiency

Ergometrine

Section

Uterotonics

Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)

Indications

Postpartum haemorrhage

Erlotinib

Section

Targeted therapies

Oral > Solid: 100 mg; 150 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Erythromycin

Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)

Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)

Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Ointment: 0.5%

Indications

Second choice

Therapeutic equivalent to [clarithromycin](#) for

Acute pharyngitis

Other indications

Bacterial infection of unspecified site

Chlamydial conjunctivitis

Gonococcal infection of eye

Erythropoiesis-stimulating agents

Section

Antianaemia medicines

Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe

Indications

Anaemia due to chronic disease

Estradiol

Section

Estrogens

Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg

Indications

Gonadotropin deficiency

Hypopituitarism

Turner syndrome

Estradiol cypionate + medroxyprogesterone acetate

Section

Injectable hormonal contraceptives

Parenteral > General injections > IM: 5 mg + 25 mg

Indications

Contact with health services for reasons associated with reproduction

Etanercept

Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Ethambutol

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

Indications

Other specified tuberculosis

Tuberculosis

Ethambutol + isoniazid

Section

Antituberculosis medicines

Oral > Solid: 400 mg + 150 mg tablet

Indications

Tuberculosis

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

Tuberculosis

Ethambutol + isoniazid + rifampicin

Section

Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

Tuberculosis

Ethanol

Section

Antiseptics

Local > Topical > Solution: 70% (denatured)

Indications

Denatured alcohol

Ether

Section

General anaesthetics and oxygen > Inhalational medicines

Respiratory > Inhalation > solution:

Indications

Anaesthetics and therapeutic gases

Ethinylestradiol + etonogestrel

Section

Intravaginal contraceptives

Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

Indications

Contact with health services for contraceptive management

Ethinylestradiol + levonorgestrel

Section

Oral hormonal contraceptives
Oral > Solid: 50 µg + 250 µg [4]
Oral > Solid: 30 µg + 150 µg

Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Ethinylestradiol + norethisterone

Section

Oral hormonal contraceptives
Oral > Solid: 35 µg + 1 mg

Indications

Contact with health services for contraceptive management

Ethionamide

Section

Antituberculosis medicines
Oral > Solid > dispersible tablet: 125 mg
Oral > Solid > tablet: 250 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Tuberculous meningitis

Ethosuximide

Section

Antiseizure medicines
Oral > Liquid: 250 mg per 5 mL
Oral > Solid: 250 mg

Indications

Absence seizures, typical

Etonogestrel-releasing implant

Section

Implantable contraceptives
Implant > Subdermal: 68 mg single rod

Indications

Contact with health services for insertion of contraceptive device

Etoposide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule

Oral > Solid: 100 mg capsule

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)

Oral > Solid: 100 mg capsule; 50 mg capsule

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Germ cell tumour of testis

Malignant trophoblastic neoplasms of placenta

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Hodgkin lymphoma

Retinoblastoma

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Everolimus

Section

Targeted therapies

Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg

Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg

Indications

Other specified gliomas of brain

Fentanyl

Section

Opioid analgesics

Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour

Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)

Oral > Other: 200 to 1200 µg buccal film (as citrate)

Indications

Chronic cancer pain

Other specified chronic cancer related pain

Ferrous salt

Section

Antianaemia medicines

Oral > Liquid: 25 mg per mL iron (as sulfate)

Oral > Solid: 60 mg iron

Indications

Iron deficiency anaemia

Ferrous salt + folic acid

Section

Antianaemia medicines

Oral > Solid: 60 mg iron + 2.8 mg

Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg

Indications

Iron deficiency anaemia

Clefts of lip, alveolus or palate

Iron deficiency anaemia

Anencephaly or similar anomalies

Spina bifida

Fexinidazole

Section

Medicines for the treatment of 1st stage African trypanosomiasis

Oral > Solid: 600 mg

Medicines for the treatment of 2nd stage African trypanosomiasis

Oral > Solid: 600 mg

Indications

African trypanosomiasis

African trypanosomiasis

Fexofenadine

Section

Antiallergics and medicines used in anaphylaxis

Indications

Therapeutic equivalent to loratadine for

Allergic or hypersensitivity conditions of unspecified type

Fifth generation cephalosporins

Section

Reserve group antibiotics

Indications

Other specified bacterial diseases

Filgrastim

Section

Immunomodulators

Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

Indications

Acquired neutropaenia

Fingolimod

Section

Immunomodulators for non-malignant disease

Oral > Solid: 0.25 mg; 0.5 mg

Indications

Relapsing-remitting multiple sclerosis

Flomoxef

Section

Watch group antibiotics

Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified other antibiotic resistant Enterobacterales

Fluconazole

Section

Antifungal medicines

Parenteral > General injections > IV: 2 mg per mL in vial

Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid

Oral > Solid > capsule: 50 mg

Indications

Cryptococcosis

Candidosis

Flucytosine

Section

Antifungal medicines

Parenteral > General injections > IV: 2.5 g per 250 mL infusion

Oral > Solid: 250 mg capsule

Indications

Cryptococcosis

Fludarabine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection

Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fludrocortisone

Section

Adrenal hormones and synthetic substitutes

Oral > Solid: 100 µg (acetate)

Indications

Adrenocortical insufficiency

Flunisolide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to **budesonide** for

Asthma

Fluorescein

Section

Diagnostic agents > Ophthalmic medicines

Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)

Indications

Fluorescein

Fluoride

Section

Dental medicines and preparations

Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)

Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)

Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)

Local > Dental > Varnish: 22500 ppm fluoride (any type)

Indications

Dental caries

Fluorouracil

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Ointment: 5%

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule

Parenteral > General injections > IV: 50 mg per mL in vial

Indications

Plantar warts

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of nasopharynx

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of breast

Malignant neoplasms of rectum

Malignant neoplasms of colon

Fluoxetine

Section

Medicines for depressive disorders

Oral > Solid: 20 mg (as hydrochloride)

Medicines for other common symptoms in palliative care

Oral > Solid: 20 mg (as hydrochloride)

Medicines for anxiety disorders

Oral > Solid: 20 mg (as hydrochloride)

Medicines for obsessive compulsive disorders

Oral > Solid: 20 mg (as hydrochloride)

Indications

Depressive disorders

Palliative care

Social anxiety disorder

Generalised anxiety disorder

Panic disorder

Obsessive-compulsive disorder

Fluphenazine

Section

Medicines for psychotic disorders

Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthatate)

Indications

Schizophrenia or other primary psychotic disorders

Flutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to bicalutamide for

Malignant neoplasms of prostate

Fluticasone

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide for

Asthma

Fluticasone + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide + formoterol for

Asthma

Fluticasone furoate + vilanterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide + formoterol for

Asthma

Fluvastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to simvastatin for

Mixed hyperlipidaemia

Therapeutic equivalent to simvastatin for

Coronary atherosclerosis

Folic acid

Section

Antianaemia medicines

Oral > Solid: 1 mg tablet; 5 mg tablet

Oral > Solid: 400 µg

Indications

Folate deficiency anaemia

Anencephaly or similar anomalies

Spina bifida

Cephalocele

Fomepizole

Section

Antidotes and other substances used in poisonings > Specific
Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule
(sulfate); 1 g per mL in 1.5 mL ampoule (base)

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Fosfomycin (injection)

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Fourth generation cephalosporins

Section

Watch group antibiotics

Indications

Other specified bacterial diseases

Fresh-frozen plasma

Section

Blood and blood components

Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Fulvestrant

Section

Hormones and antihormones

Parenteral > General injections > IV: 250 mg per 5 mL

Indications

Malignant neoplasms of breast

Furosemide

Section

Medicines used in heart failure

Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL

Oral > Solid > tablet: 40 mg; 20 mg

Diuretics

Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL

Oral > Solid > tablet: 40 mg; 20 mg

Indications

Heart failure

Anuria or oliguria

Oedema

Gabapentin

Section

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg

Indications

Neuropathic pain

Gallamine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)

Indications

Muscle relaxants

Gatifloxacin

Section

Antituberculosis medicines
Oral > Solid: 200 mg; 400 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Gefitinib

Section

Targeted therapies

Indications

Therapeutic equivalent to erlotinib for

Other specified malignant neoplasms of bronchus or lung

Gemcitabine

Section

Cytotoxic medicines
Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Gentamicin

Section

Access group antibiotics
Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

Neonatal meningitis

co-prescribed with amoxicillin

Sepsis without septic shock

co-prescribed with amoxicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Sepsis without septic shock

co-prescribed with ampicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with ampicillin

Peritoneal abscess (severe)

co-prescribed with ampicillin

Peritonitis (mild-moderate)

co-prescribed with ampicillin

Peritonitis (severe)

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)

co-prescribed with ampicillin

Peritoneal abscess (mild-moderate)

co-prescribed with benzylpenicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with benzylpenicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with benzylpenicillin

Sepsis without septic shock

Second choice

Other specified prophylactic measures

Gonococcal infection

Other indications

Bacterial infection of unspecified site

Other specified conjunctivitis

Infectious blepharitis

Glass ionomer cement

Section

Dental medicines and preparations

Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid

Indications

Dental caries

Glatiramer acetate

Section

Medicines for multiple sclerosis

Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL

Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe

Indications

Relapsing-remitting multiple sclerosis

Multiple sclerosis

Glecaprevir + pibrentasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 50 mg + 20 mg granules

Oral > Solid > tablet: 100 mg + 40 mg

Indications

Chronic hepatitis C

Glibenclamide

Section

Oral hypoglycaemic agents

Oral > Solid: 5 mg; 2.5 mg

Indications

Type 2 diabetes mellitus

Gliclazide

Section

Oral hypoglycaemic agents

Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release

Indications

Type 2 diabetes mellitus

Glucagon

Section

Medicines for hypoglycaemia

Parenteral > General injections > unspecified: 1 mg per mL

Indications

Hypoglycaemia in the context of diabetes

Glucose

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

Parenteral > General injections > IV: 5% isotonic; 10% hypertonic

Parenteral > General injections > IV: 50% hypertonic

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Hypoglycaemia without associated diabetes

Glucose + sodium chloride

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na⁺ 30 mmol/L and Cl⁻ 30 mmol/L; 5% + 0.9% (equivalent to Na⁺ 150 mmol/L and Cl⁻ 150 mmol/L); 5% + 0.45% (equivalent to Na⁺ 75 mmol/L and Cl⁻ 75 mmol/L)

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Glutaral

Section

Disinfectants

Local > Topical > Solution: 2%

Indications

Glutaral nonmedicinal

Glyceryl trinitrate

Section

Antianginal medicines

Oral > Solid: 500 µg sublingual tablet

Indications

Angina pectoris

Glycopyrronium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) for

Chronic obstructive pulmonary disease

Golimumab

Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Goserelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [leuprorelin](#) for

Malignant neoplasms of breast

Therapeutic equivalent to [leuprorelin](#) for

Malignant neoplasms of prostate

Granisetron

Section

Medicines for other common symptoms in palliative care

Antiemetic medicines

Indications

Therapeutic equivalent to ondansetron for

Palliative care

Therapeutic equivalent to ondansetron for

Nausea or vomiting

Griseofulvin

Section

Antifungal medicines

Oral > Liquid: 125 mg per 5 mL

Oral > Solid: 125 mg; 250 mg

Indications

Dermatophytosis

Haemophilus influenzae type b vaccine

Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against single bacterial diseases

Haloperidol

Section

Medicines for other common symptoms in palliative care

Oral > Liquid: 2 mg per mL

Oral > Solid: 0.5 mg; 2 mg; 5 mg

Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule

Medicines for psychotic disorders

Parenteral > General injections > IM: 5 mg per mL in ampoule

Oral > Solid: 2 mg; 5 mg

Indications

Palliative care

Schizophrenia or other primary psychotic disorders

Haloperidol decanoate

Section

Medicines for psychotic disorders

Indications

Therapeutic equivalent to fluphenazine for

Schizophrenia or other primary psychotic disorders

Halothane

Section

General anaesthetics and oxygen > Inhalational medicines
Respiratory > Inhalation > liquid:

Indications

Anaesthetics and therapeutic gases

Heparin sodium

Section

Medicines affecting coagulation
Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule;
20000 IU per mL in 1 mL ampoule; 5000 IU per mL in 1 mL ampoule

Indications

Venous thromboembolism

Unstable angina

Acute ischaemic heart disease

Hepatitis A vaccine

Section

Recommendations for some high-risk populations
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against viral hepatitis

Hepatitis B vaccine

Section

Recommendations for all immunization programmes
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against viral hepatitis

Homatropine

Section

Ophthalmological preparations > Mydriatics
Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)

Indications

Anterior uveitis

Therapeutic equivalent to *atropine* for

Anterior uveitis

Human papilloma virus (HPV) vaccine

Section

Recommendations for all immunization programmes
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Hydralazine

Section

Antihypertensive medicines

Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)

Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)

Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)

Indications

Essential hypertension

Gestational hypertension

Hydrochlorothiazide

Section

Antihypertensive medicines

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 25 mg; 12.5 mg

Medicines used in heart failure

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 25 mg

Diuretics

Oral > Solid: 25 mg

Indications

Essential hypertension

Heart failure

Oedema

Hydrocortisone

Section

Hormones and antihormones

Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)

Adrenal hormones and synthetic substitutes

Oral > Solid: 5 mg; 10 mg; 20 mg

Ophthalmological preparations > Anti-inflammatory agents

Local > Ophthalmological > Ointment: 1% (acetate)

Antiallergics and medicines used in anaphylaxis

Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)

Anti-inflammatory medicines

Local > Rectal > Suppository: 25 mg (acetate)

Local > Rectal > Retention enema: 100 mg per 60 mL

Dermatological medicines > Anti-inflammatory and antipruritic medicines

Local > Topical > Cream: 1% (acetate)

Local > Topical > Ointment: 1% (acetate)

Indications

Lymphoid leukaemia, not elsewhere classified

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Adrenocortical insufficiency

Scleritis

Anterior uveitis

Anaphylaxis

Crohn disease site

Ulcerative colitis

Dermatitis or eczema

Lichen planus

Pruritus due to skin disorder

Psoriasis of unspecified type

Hydromorphone

Section

Opioid analgesics

Indications

Therapeutic equivalent to morphine for

Pain

Hydroxocobalamin

Section

Antianaemia medicines

Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)

Indications

Megaloblastic anaemia due to vitamin B12 deficiency

Hydroxycarbamide (hydroxyurea)

Section

Cytotoxic medicines

Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg

Other medicines for haemoglobinopathies

Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

Indications

Squamous cell carcinoma of oropharynx

Chronic myeloid leukaemia, not elsewhere classified

Other specified sickle cell disorders or other haemoglobinopathies

Hydroxychloroquine

Section

Antimalarial medicines > For chemoprevention

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 200 mg (as sulfate)

Indications

Therapeutic equivalent to chloroquine for

Malaria due to Plasmodium falciparum

Systemic lupus erythematosus

Cutaneous lupus erythematosus of unspecified type

Hyoscine butylbromide

Section

Medicines for other common symptoms in palliative care

Parenteral > General injections > unspecified: 20 mg per mL injection

Indications

Palliative care

Hyoscine hydrobromide

Section

Medicines for other common symptoms in palliative care

Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch

Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection

Indications

Palliative care

Hypochlorous acid

Section

Antiseptics

Local > Topical > Solution:

Indications

Disinfectant, not elsewhere classified

Hypromellose

Section

Ophthalmological preparations

Local > Ophthalmological > Solution (eye drops): 0.3%

Indications

Keratoconjunctivitis sicca

Ibrutinib

Section

Targeted therapies

Oral > Solid: 140 mg

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ibuprofen

Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 5 mg per mL

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL

Oral > Solid > tablet: 200 mg; 400 mg; 600 mg

Antimigraine medicines > For treatment of acute attack

Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL

Oral > Solid > tablet: 200 mg; 400 mg

Indications

Patent arterial duct

Pain

Migraine

Idoxuridine

Section

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Solution (eye drops): 0.1%

Local > Ophthalmological > Ointment: 0.2%

Indications

Herpes simplex keratitis

Ifosfamide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Imatinib

Section

Targeted therapies

Oral > Solid: 100 mg; 400 mg

Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Chronic myeloid leukaemia, not elsewhere classified

Imipenem + cilastatin

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Antituberculosis medicines

Indications

Second choice

Therapeutic equivalent to meropenem for

Neutropenia (high-risk)

Therapeutic equivalent to meropenem for

Peritoneal abscess (severe)

Therapeutic equivalent to meropenem for

Peritonitis (severe)

Other indications

Pseudomonas aeruginosa resistant to other antibiotic

Antibiotic resistant Acinetobacter baumannii

Therapeutic equivalent to meropenem for

Multi-drug resistant Mycobacterium tuberculosis

Imipenem + cilastatin + relebactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection

Indications

Other specified other antibiotic resistant Enterobacterales

Carbapenem resistant Enterobacterales

Carbapenem-resistant Pseudomonas aeruginosa

Indapamide

Section

Antihypertensive medicines

Indications

Therapeutic equivalent to hydrochlorothiazide for

Essential hypertension

Medicines used in heart failure

Therapeutic equivalent to hydrochlorothiazide for

Heart failure

Indinavir

Section

Antiretrovirals > Protease inhibitors
Oral > Solid: 400 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Indometacin

Section

Medicines administered to the neonate [c]

Indications

Therapeutic equivalent to ibuprofen for

Patent arterial duct

Infliximab

Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Influenza vaccine (seasonal)

Section

Recommendations for immunization programmes with certain characteristics
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against influenza

Insulin

Section

Insulins
Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen (soluble)

Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

Insulin analogues

Section

Insulins
Not specified

Indications

Type 1 diabetes mellitus

Type 2 diabetes mellitus

Insulin degludec

Section

Insulins
Parenteral > General injections > SC: 100 units per mL

Indications

Therapeutic equivalent to [insulin glargine](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to long-acting insulin analogues for

Type 1 diabetes mellitus

Therapeutic equivalent to long-acting insulin analogues for

Type 2 diabetes mellitus

Insulin detemir

Section

Insulins

Indications

Therapeutic equivalent to [insulin glargine](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to long-acting insulin analogues for

Type 1 diabetes mellitus

Therapeutic equivalent to long-acting insulin analogues for

Type 2 diabetes mellitus

Insulin glargine

Section

Insulins
Parenteral > General injections > SC: 100 units per mL

Indications

Type 1 diabetes mellitus

Therapeutic equivalent to long-acting insulin analogues for

Type 1 diabetes mellitus

Therapeutic equivalent to long-acting insulin analogues for

Type 2 diabetes mellitus

Intermediate-acting insulin

Section

Insulins

Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin

Indications

Type 1 diabetes mellitus

Type 2 diabetes mellitus

Intraperitoneal dialysis solution

Section

Peritoneal dialysis solution
parenteral solution

Indications

Care involving peritoneal dialysis

Iodine

Section

Vitamins and minerals

Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule

Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle

Oral > Solid: 190 mg

Antiseptics

Indications

Iodine deficiency

Therapeutic equivalent to povidone iodine for

Povidone iodine

Iohexol

Section

Diagnostic agents > Radiocontrast media

Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule

Indications

X-ray contrast media, iodinated

Ipecacuanha

Section

Antidotes and other substances used in poisonings > Non-specific

Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine

Indications

Unspecified injury, poisoning or certain other consequences of external causes

Ipratropium bromide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease
Respiratory > Inhalation > aerosol: 20 µg per dose

Indications

Asthma

Chronic obstructive pulmonary disease

Irinotecan

Section

Cytotoxic medicines
Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Isoflurane

Section

General anaesthetics and oxygen > Inhalational medicines
Respiratory > Inhalation > liquid:

Indications

Anaesthetics and therapeutic gases

Isoniazid

Section

Antituberculosis medicines
Parenteral > General injections > IV: 100 mg per mL
Oral > Solid > dispersible tablet: 100 mg
Oral > Solid > tablet: 100 mg; 300 mg

Indications

Other specified tuberculosis

Tuberculosis

Isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines
Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg

Indications

Tuberculosis

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section

Medicines for prevention of HIV-related opportunistic infections
Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

Indications

Other specified prophylactic measures

Isoniazid + rifampicin

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 50 mg + 75 mg

Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg

Indications

Tuberculosis

Isoniazid + rifapentine

Section

Antituberculosis medicines

Oral > Solid: 300 mg + 300 mg tablet (scored)

Indications

Latent tuberculosis

Isoprenaline

Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)

Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)

Indications

Bradycardia

Cardiogenic shock

Isosorbide dinitrate

Section

Antianginal medicines

Oral > Solid: 5 mg sublingual tablet

Indications

Angina pectoris

Itraconazole

Section

Antifungal medicines

Oral > Liquid: 10 mg per mL

Oral > Solid: 100 mg

Indications

Chronic pulmonary aspergillosis

Chromoblastomycosis

Histoplasmosis

Talaromycosis

Sporotrichosis

Paracoccidioidomycosis

Ivermectin

Section

Intestinal anthelmintics
Oral > Solid > tablet: 3 mg

Antifilarials
Oral > Solid > tablet: 3 mg

Medicines for ectoparasitic infections
Oral > Solid > tablet: 3 mg

Indications

Strongyloidiasis

Ascariasis

Trichuriasis

Hookworm diseases

Ancylostomiasis

Onchocerciasis

Lymphatic filariasis

Scabies

Kanamycin

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to gentamicin for

Other specified conjunctivitis

Therapeutic equivalent to gentamicin for

Infectious blepharitis

Kanamycin (injection)

Section

Antituberculosis medicines
Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

Multi-drug resistant Mycobacterium tuberculosis

Ketamine

Section

General anaesthetics and oxygen > Injectable medicines
Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)

Indications

Anaesthetics and therapeutic gases

Ketoconazole

Section

Medicines for endocrine disorders
Oral > Solid > tablet: 200 mg

Indications

Cushing syndrome

Lactulose

Section

Medicines for other common symptoms in palliative care
Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid

Indications

Palliative care

Lamivudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Liquid: 50 mg per 5 mL
Oral > Solid: 150 mg tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + nevirapine + zidovudine

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Indications

Therapeutic equivalent to emtricitabine + tenofovir for

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to emtricitabine + tenofovir for

Contact with or exposure to human immunodeficiency virus

Lamivudine + zidovudine

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamotrigine

Section

Antiseizure medicines

Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)

Indications

Epilepsy or seizures

Latanoprost

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops

Indications

Primary open-angle glaucoma

Ledipasvir + sofosbuvir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 90 mg + 400 mg tablet

Indications

Chronic hepatitis C

Lenalidomide

Section

Immunomodulators

Oral > Solid: 25 mg

Indications

Plasma cell myeloma

Letrozole

Section

Ovulation inducers

Oral > Solid > dosage form: 2.5 mg

Indications

Female infertility without specification whether primary or secondary

Leuprorelin

Section

Hormones and antihormones

Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

Levamisole

Section

Intestinal anthelmintics

Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)

Indications

Ascariasis

Levetiracetam

Section

Antiseizure medicines

Oral > Liquid: 100 mg per mL

Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg

Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag

Indications

Epilepsy or seizures

Status epilepticus

Levodopa

Section

Antiseizure medicines

Oral > Solid: 250 mg

Indications

Parkinson disease

Levodopa + benserazide

Section

Medicines for parkinsonism

Indications

Therapeutic equivalent to levodopa + carbidopa for

Parkinson disease

Levodopa + carbidopa

Section

Medicines for parkinsonism

Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet

Indications

Parkinson disease

Levofloxacin

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 250 mg; 500 mg; 750 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Levonorgestrel

Section	Indications
<p>Oral hormonal contraceptives</p> <p>Oral > Solid: 750 µg [2]; 1.5 mg [1]</p> <p>Oral > Solid: 30 µg</p>	<p>Contact with health services for postcoital contraception</p> <p>Contact with health services for contraceptive management</p>
<p>Intrauterine devices</p> <p>Intrauterine system with reservoir containing 52 mg of levonorgestrel.</p>	<p>Contact with health services for insertion of contraceptive device</p>

Levonorgestrel-releasing implant

Section	Indications
<p>Implantable contraceptives</p> <p>Implant > Subdermal: 75 mg per rod (two-rods)</p>	<p>Contact with health services for insertion of contraceptive device</p>

Levothyroxine

Section	Indications
<p>Thyroid hormones and antithyroid medicines</p> <p>Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)</p>	<p>Hypothyroidism</p>

Lidocaine

Section	Indications
<p>Antiarrhythmic medicines</p> <p>Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)</p>	<p>Ventricular tachyarrhythmia</p>
<p>Local anaesthetics</p> <p>Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution</p> <p>Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)</p> <p>Local > Topical > unspecified: 2 to 4% (hydrochloride)</p>	<p>Local anaesthetics</p>

Lidocaine + epinephrine

Section

Local anaesthetics

Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial

Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine

Indications

Local anaesthetics

Lindane

Section

Dermatological medicines > Scabicides and pediculicides

Local > Topical > Cream: 1%

Local > Topical > Lotion: 1%

Indications

Scabies

Linezolid

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 mg per mL in 300 mL bag

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 400 mg tablet; 600 mg tablet

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 600 mg

Antituberculosis medicines

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 600 mg

Indications

Other specified bacterial diseases

Methicillin resistant *Staphylococcus aureus*

Vancomycin resistant *Staphylococcus aureus*

Vancomycin resistant *Enterococcus*

Multi-drug resistant *Mycobacterium tuberculosis*

Liraglutide

Section

Medicines for endocrine disorders

Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen

Indications

Obesity

Lisinopril + amlodipine

Section

Antihypertensive medicines

Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg

Indications

Essential hypertension

Lisinopril + hydrochlorothiazide

Section

Antihypertensive medicines

Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg

Indications

Essential hypertension

Lisocabtagene maraleucel

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to axicabtagene ciloleucel for

Diffuse large B-cell lymphomas

Lithium carbonate

Section

Medicines for bipolar disorders

Oral > Solid: 300 mg

Indications

Bipolar or related disorders

Long-acting insulin analogues

Section

Insulins

Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Type 1 diabetes mellitus

Type 2 diabetes mellitus

Loperamide

Section

Medicines for other common symptoms in palliative care

Oral > Solid > dosage form: 2 mg

Indications

Palliative care

Lopinavir + ritonavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)

Oral > Solid > dosage form: 40 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Loratadine

Section

Antiallergics and medicines used in anaphylaxis

Oral > Liquid: 1 mg per mL

Oral > Solid: 10 mg

Indications

Allergic or hypersensitivity conditions of unspecified type

Lorazepam

Section

Antiseizure medicines

Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule

Medicines for anxiety disorders

Indications

Status epilepticus

Therapeutic equivalent to [diazepam](#) for

Anxiety

Losartan

Section

Antihypertensive medicines

Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet

Medicines used in heart failure

Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet

Indications

Essential hypertension

Heart failure

Lovastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to [simvastatin](#) for

Mixed hyperlipidaemia

Therapeutic equivalent to [simvastatin](#) for

Coronary atherosclerosis

Lugol's solution

Section

Thyroid hormones and antithyroid medicines

Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)

Indications

Thyrotoxicosis

Magnesium sulfate

Section

Antiseizure medicines

Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)

Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)

Indications

Severe pre-eclampsia

Eclampsia

Mannitol

Section

Diuretics

Parenteral > General injections > IV: 10% solution; 20% solution

Indications

Ocular hypertension

Cerebral oedema

Measles vaccine

Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against measles alone

Mebendazole

Section

Intestinal anthelmintics

Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

Cysticidal medicines

Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

Indications

Ascariasis

Enterobiasis

Trichuriasis

Hookworm diseases

Other specified echinococcosis

Medroxyprogesterone acetate

Section

Injectable hormonal contraceptives

Parenteral > General injections > IM: 150 mg per mL in 1 mL vial

Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system

Progestogens

Oral > Solid: 5 mg

Indications

Contact with health services for reasons associated with reproduction

Excessive menstruation with irregular cycle

Mefloquine

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 250 mg tablet (hydrochloride)

Antimalarial medicines > For chemoprevention

Oral > Solid: 250 mg tablet (hydrochloride)

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Malaria due to *Plasmodium falciparum*

Meglumine antimoniate

Section

Antileishmaniasis medicines

Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule

Indications

Visceral leishmaniasis

Cutaneous leishmaniasis

Mucocutaneous leishmaniasis

Meglumine iotroxate

Section

Diagnostic agents > Radiocontrast media

Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL

Indications

X-ray contrast media, iodinated

Melarsoprol

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)

Indications

African trypanosomiasis

Melphalan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection

Oral > Solid: 2 mg

Indications

Plasma cell myeloma

Meningococcal meningitis vaccine

Section

Recommendations for some high-risk populations

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against single bacterial diseases

Mercaptopurine

Section

Cytotoxic medicines

Oral > Solid: 50 mg tablet

Oral > Liquid: 20 mg per mL

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, not elsewhere classified

Langerhans cell histiocytosis

Meropenem

Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Antituberculosis medicines

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choice

Neutropenia (high-risk)

Peritoneal abscess (severe)

Peritonitis (severe)

Neonatal meningitis

Multi-drug resistant *Mycobacterium tuberculosis*

Meropenem + vaborbactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Carbapenem resistant *Acinetobacter baumannii*

Mesalazine

Section

Anti-inflammatory medicines

Indications

Therapeutic equivalent to sulfasalazine for

Crohn disease site

Therapeutic equivalent to sulfasalazine for

Ulcerative colitis

Mesna

Section

Supportive medicines

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule

Oral > Solid: 400 mg; 600 mg

Indications

Osteosarcoma of bone and articular cartilage of other specified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Metformin

Section

Oral hypoglycaemic agents

Oral > Solid: 500 mg (hydrochloride)

Indications

Type 2 diabetes mellitus

Methadone

Section

Medicines for opioid use disorders

Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)

Opioid analgesics

Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)

Oral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)

Indications

Opioid dependence

Chronic cancer pain

Methimazole

Section

Thyroid hormones and antithyroid medicines

Oral > Solid: 5 mg; 10 mg; 20 mg

Indications

Thyrotoxicosis

Methionine

Section

Antidotes and other substances used in poisonings > Specific
Oral > Solid: 250 mg (DL)

Indications

Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

Methotrexate

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

Oral > Solid: 2.5 mg (as sodium salt)

Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid > tablet: 2.5 mg (as sodium salt)

Immunomodulators for non-malignant disease

Parenteral > General injections > SC: pre-filled syringe in multiple strengths

Medicines for juvenile joint diseases

Oral > Solid > tablet: 2.5 mg (as sodium salt)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Malignant trophoblastic neoplasms of placenta

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Psoriasis of unspecified type

Rheumatoid arthritis, serology unspecified

Crohn disease site

Psoriatic arthritis

Juvenile idiopathic arthritis

Methoxy polyethylene glycol-epoetin beta

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Methyldopa

Section

Antihypertensive medicines

Oral > Solid: 250 mg

Indications

Essential hypertension

Gestational hypertension

Methylergometrine

Section

Uterotonics

Indications

Therapeutic equivalent to [ergometrine](#) for

Postpartum haemorrhage

Methylphenidate

Section

Medicines for mental and behavioural disorders

Multiple formulations and strengths.

Indications

Attention deficit hyperactivity disorder

Methylprednisolone

Section

Hormones and antihormones

Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)

Indications

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Methylthionium chloride

Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule

Indications

Acquired methaemoglobinaemia

Metoclopramide

Section

Medicines for other common symptoms in palliative care

Oral > Liquid: 5 mg per 5 mL

Oral > Solid: 10 mg (hydrochloride)

Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)

Antiemetic medicines

Oral > Liquid: 5 mg per 5 mL

Oral > Solid: 10 mg (hydrochloride)

Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)

Indications

Palliative care

Nausea or vomiting

Metoprolol

Section

Antianginal medicines

Therapeutic equivalent to bisoprolol for

Angina pectoris

Medicines used in heart failure

Therapeutic equivalent to bisoprolol for

Heart failure

Antihypertensive medicines

Therapeutic equivalent to bisoprolol for

Essential hypertension

Antiarrhythmic medicines

Therapeutic equivalent to bisoprolol for

Cardiac arrhythmia

Metronidazole

Section

Access group antibiotics

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Oral > Solid: 200 to 500 mg tablet

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
Injection

Local > Rectal > Suppository: 500 mg; 1 g

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Antiamoebic and anti giardiasis medicines

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Parenteral > General injections > unspecified: 500 mg in 100 mL vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Indications

First choice

Intestinal infections due to *Clostridioides difficile*

Trichomoniasis

co-prescribed with cefazolin

Other specified prophylactic measures

co-prescribed with cefotaxime

Peritonitis (severe)

co-prescribed with cefotaxime

Peritonitis (mild-moderate)

co-prescribed with cefotaxime

Peritoneal abscess (mild-moderate)

co-prescribed with cefotaxime

Peritoneal abscess (severe)

co-prescribed with ceftriaxone

Necrotising fasciitis

co-prescribed with ceftriaxone

Peritonitis (severe)

co-prescribed with ceftriaxone

Peritoneal abscess (mild-moderate)

co-prescribed with ceftriaxone

Peritoneal abscess (severe)

co-prescribed with ceftriaxone

Peritonitis (mild-moderate)

Second choice

co-prescribed with ciprofloxacin

Peritonitis (mild-moderate)

co-prescribed with ciprofloxacin

Peritoneal abscess (mild-moderate)

Other indications

Bacterial infection of unspecified site

Amoebiasis

Micafungin

Section

Antifungal medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection

Indications

Systemic or invasive candidosis

Miconazole

Section

Dermatological medicines > Antifungal medicines

Local > Topical > Cream: 2% (nitrate)

Local > Topical > Ointment: 2% (nitrate)

Indications

Fungal infection of the skin

Midazolam

Section

Antiseizure medicines

Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)

Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)

Preoperative medication and sedation for short-term procedures

Parenteral > General injections > IV: 1 mg per mL

Oral > Liquid: 2 mg per mL

Oral > Solid > dosage form: 15 mg; 7.5 mg

Medicines for other common symptoms in palliative care

Oral > Liquid: 2 mg per mL

Parenteral > General injections > unspecified: 1 mg per mL; 5 mg per mL

Oral > Solid > dosage form: 7.5 mg; 15 mg

Indications

Therapeutic equivalent to [lorazepam](#) for

Status epilepticus

Status epilepticus

Sedative-hypnotic and anxiolytic drugs

Palliative care

Mifepristone - misoprostol

Section

Uterotonics

Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package

Indications

Induced abortion

Unspecified time of fetal death, cause not specified

Miltefosine

Section

Antileishmaniasis medicines

Oral > Solid: 10 mg; 50 mg

Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

Misoprostol

Section

Uterotonics

Oral > Solid: 200 µg

Local > Vaginal > tablet: 25 µg

Indications

Spontaneous abortion, incomplete, without complication

Unspecified obstetric condition

Postpartum haemorrhage

Mometasone

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide for

Asthma

Mometasone + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide + formoterol for

Asthma

Morphine

Section

Opioid analgesics

Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)

Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)

Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)

Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)

Preoperative medication and sedation for short-term procedures

Parenteral > General injections > IV: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)

Indications

Pain

Opioids or related analgesics and agents affecting opioid receptors

Moxifloxacin

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 400 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Tuberculosis

Multiple micronutrient powder

Section

Vitamins and minerals

Sachets containing:

- iron (elemental) 12.5 mg (as coated ferrous fumarate)
- zinc (elemental) 5 mg
- vitamin A 300 micrograms
- with or without other micronutrients at recommended daily values

Indications

Iron deficiency anaemia

Multiple micronutrient supplement

Section

Other medicines administered to the mother

Tablet containing:

Vit A: 800 mcg retinol activity equivalent

Vit C: 70 mg

Vit D: 5 mcg (200 IU)

Vit E: 10 mg alpha tocopherol equivalent

Vit B1: 1.4 mg

Vit B2: 1.4 mg

Vit B3: 18 mg niacin equivalent

Vit B6: 1.9 mg

Folic acid: 400 mcg

Vit B12: 2.6 mcg

Iron: 30 mg

Iodine: 150 mcg

Zinc: 15 mg

Selenium: 65 mcg

Copper: 2 mg

Indications

Maternal care for other specified conditions predominantly related to pregnancy

Mumps vaccine

Section

Recommendations for immunization programmes with certain characteristics

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against mumps alone

Mupirocin

Section

Dermatological medicines > Anti-infective medicines

Local > Topical > Cream: 2% (as mupirocin calcium)

Local > Topical > Ointment: 2%

Indications

Superficial bacterial folliculitis

Impetigo

Nadroparin

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to enoxaparin for

Acute ischaemic heart disease

Therapeutic equivalent to enoxaparin for

Venous thromboembolism

Nalidixic acid

Section

Anti-infective medicines

Oral > Solid: 250 mg; 500 mg

Indications

Shigella resistant to unspecified antibiotic

Naloxone

Section

Antidotes and other substances used in poisonings > Specific
Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule
(naloxone hydrochloride)

Indications

Unintentional exposure to or harmful effects of
opioids or related analgesics

Naltrexone

Section

Medicines for alcohol use disorders
Parenteral > General injections > IM: 380 mg in vial (extended-release)
Oral > Solid > tablet: 50 mg

Indications

Disorders due to use of alcohol

Natamycin

Section

Ophthalmological preparations > Anti-infective agents
Local > Ophthalmological > Suspension: 5% eye drops

Indications

Infectious keratitis

Nelfinavir

Section

Antiretrovirals > Protease inhibitors
Oral > Solid: 250 mg (as mesilate)
Oral > Other: 50 mg per g oral powder

Indications

Human immunodeficiency virus disease
without mention of associated disease or
condition, clinical stage unspecified

Neostigmine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
Oral > Solid: 15 mg (neostigmine bromide)
Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)

Indications

Myasthenia gravis

Anticholinesterase reversible

Netilmicin

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to gentamicin for

Other specified conjunctivitis

Therapeutic equivalent to gentamicin for

Infectious blepharitis

Nevirapine

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
Oral > Liquid: 50 mg per 5 mL
Oral > Solid > dispersible tablet: 50 mg
Oral > Solid > tablet: 200 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Niclosamide

Section

Intestinal anthelmintics
Oral > Solid: 500 mg tablet (chewable)

Indications

Hymenolepiasis

Diphyllobothriasis

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

Nicotinamide

Section

Vitamins and minerals
Oral > Solid: 50 mg

Indications

Pellagra

Nicotine replacement therapy

Section

Medicines for nicotine use disorders

Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour

Oral > Solid > lozenge: 2 mg; 4 mg lozenge

Local > Buccal > Oral spray: 1 mg per actuation

Local > Buccal > Chewing gum: 2 mg; 4 mg

Indications

Nicotine dependence

Nifedipine

Section

Antioxytocs (tocolytics)

Oral > Solid: 10 mg (immediate-release)

Antianginal medicines

Oral > Solid: 10 mg

Antihypertensive medicines

Oral > Solid: 10 mg tablet; sustained-release formulations

Indications

Preterm labour without delivery

Angina pectoris

Essential hypertension

Nifurtimox

Section

American trypanosomiasis

Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

Medicines for the treatment of 2nd stage African trypanosomiasis

Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

Indications

Chagas disease

African trypanosomiasis

Nilotinib

Section

Targeted therapies

Oral > Solid > capsule: 150 mg; 200 mg

Indications

Chronic myeloid leukaemia, not elsewhere classified

Nilutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to bicalutamide for

Malignant neoplasms of prostate

Nitrofurantoin

Section

Access group antibiotics

Oral > Liquid: 25 mg per 5 mL oral liquid

Oral > Solid > dosage form: 100 mg; 50 mg

Indications

First choice

Infectious cystitis

Nitrous oxide

Section

General anaesthetics and oxygen > Inhalational medicines

Respiratory > Inhalation:

Indications

Anaesthetics and therapeutic gases

Nivolumab

Section

Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Melanoma of skin

Norethisterone

Section

Oral hormonal contraceptives

Oral > Solid: 350 µg

Progestogens

Oral > Solid: 5 mg

Indications

Contact with health services for contraceptive management

Excessive menstruation with irregular cycle

Therapeutic equivalent to medroxyprogesterone acetate for

Excessive menstruation with irregular cycle

Norethisterone enantate

Section

Injectable hormonal contraceptives

Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

Indications

Contact with health services for reasons associated with reproduction

Normal immunoglobulin

Section

Human immunoglobulins

Parenteral > General injections > IV: 5% protein solution; 10% protein solution

Parenteral > General injections > IM: 16% protein solution

Parenteral > General injections > SC: 15% protein solution; 16% protein solution

Indications

Primary immunodeficiencies

Mucocutaneous lymph node syndrome

Langerhans cell histiocytosis

Nystatin

Section

Antifungal medicines

Oral > Liquid: 100000 IU per mL

Local > Topical > Other: 100000 IU pessary

Oral > Solid > dosage form: 500000 IU

Oral > Solid > lozenge: 100000 IU

Indications

Candidosis

Ocrelizumab

Section

Medicines for multiple sclerosis

Parenteral > General injections > IV: 30 mg per mL in 10 mL vial

Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution

Indications

Relapsing-remitting multiple sclerosis

Multiple sclerosis

Octreotide

Section

Medicines for disorders of the pituitary hormone system

Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent

Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)

Indications

Acromegaly or pituitary gigantism

Ofloxacin

Section

Antituberculosis medicines

Oral > Solid: 200 mg; 400 mg

Ear, nose and throat medicines [c]

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Solution (eye drops): 0.3%

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Therapeutic equivalent to ciprofloxacin for

Infectious diseases of external ear

Other specified conjunctivitis

Infectious keratitis

Olanzapine

Section

Medicines for psychotic disorders

Parenteral > General injections > IM: 10 mg in vial powder for injection

Indications

Therapeutic equivalent to risperidone for

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

Omadacycline

Section

Reserve group antibiotics

Parenteral > General injections > IV: 100 mg lyophilized powder for injection

Oral > Solid: 300 mg

Indications

Methicillin resistant *Staphylococcus aureus*

Ombitasvir + paritaprevir + ritonavir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

Indications

Chronic hepatitis C

Omeprazole

Section

Antiulcer medicines

Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid

Oral > Solid: 10 mg; 20 mg; 40 mg

Parenteral > General injections > IV: 40 mg in vial

Indications

Peptic ulcer, site unspecified

Gastro-oesophageal reflux disease

Gastrointestinal bleeding

Ondansetron

Section

Medicines for other common symptoms in palliative care

Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)

Oral > Liquid: 4 mg per 5 mL (ondansetron base)

Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)

Antiemetic medicines

Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)

Oral > Liquid: 4 mg per 5 mL (ondansetron base)

Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)

Indications

Palliative care

Nausea or vomiting

Oral rehydration salts

Section

Oral rehydration

Powder for dilution in 200 mL, 500 mL, 1 L:

- glucose 75 mEq
- sodium 75 mEq or mmol/L
- chloride 65 mEq or mmol/L
- potassium 20 mEq or mmol/L
- citrate 10 mmol/L
- osmolarity 245 mOsm/L
- glucose 13.5 g/L
- sodium chloride 2.6 g/L
- potassium chloride 1.5 g/L
- trisodium citrate dihydrate 2.9 g/L

Solutions correcting water, electrolyte and acid-base disturbances > Oral

Powder for dilution in 200 mL, 500 mL, 1 L:

- glucose 75 mEq
- sodium 75 mEq or mmol/L
- chloride 65 mEq or mmol/L
- potassium 20 mEq or mmol/L
- citrate 10 mmol/L
- osmolarity 245 mOsm/L
- glucose 13.5 g/L
- sodium chloride 2.6 g/L
- potassium chloride 1.5 g/L
- trisodium citrate dihydrate 2.9 g/L

Indications

Diarrhoea

Other specified disorders of fluid, electrolyte or acid-base balance

Oral rehydration salts - zinc sulfate

Section

Medicines used in diarrhoea

Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)

Indications

Diarrhoea

Oseltamivir

Section

Other antivirals

Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)

Indications

Influenza due to identified seasonal influenza virus

Osimertinib

Section

Targeted therapies

Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

Indications

Other specified malignant neoplasms of bronchus or lung

Oxaliplatin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

Oxamniquine

Section

Antischistosomes and other antitremitode medicines

Oral > Liquid: 250 mg per 5 mL

Oral > Solid > capsule: 250 mg

Indications

Schistosomiasis due to *Schistosoma mansoni*

Oxazolindinones

Section

Reserve group antibiotics

.

Indications

Other specified bacterial diseases

Oxycodone

Section

Opioid analgesics

Indications

Therapeutic equivalent to [morphine](#) for

Pain

Oxygen

Section

General anaesthetics and oxygen > Inhalational medicines

Respiratory > Inhalation: (medical gas)

Medical gases

Respiratory > Inhalation:

Indications

Anaesthetics and therapeutic gases

Respiratory failure as acute or chronic

Oxytetracycline

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to tetracycline for

Other specified conjunctivitis

Therapeutic equivalent to tetracycline for

Infectious keratitis

Therapeutic equivalent to tetracycline for

Infectious blepharitis

Therapeutic equivalent to tetracycline for

Trachoma

Oxytocin

Section

Uterotonics

Parenteral > General injections > unspecified: 10 IU per mL

Indications

Postpartum haemorrhage

P-aminosalicylate sodium

Section

Antituberculosis medicines

Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)
powder for oral solution

Indications

Multi-drug resistant Mycobacterium tuberculosis

P-aminosalicylic acid

Section

Antituberculosis medicines

Oral > Solid: 4 g granules in sachet

Indications

Multi-drug resistant Mycobacterium tuberculosis

Paclitaxel

Section

Cytotoxic medicines

Parenteral > General injections > IV: 6 mg per mL

Indications

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Kaposi sarcoma of unspecified primary site

Other specified malignant neoplasms of breast

Other specified carcinomas of ovary

Malignant neoplasms of breast

Malignant neoplasms of cervix uteri

Palbociclib

Section

Targeted therapies

Oral > Solid: 75 mg; 100 mg; 125 mg

Indications

Other specified malignant neoplasms of breast

Paliperidone

Section

Medicines for psychotic disorders

Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)

Indications

Therapeutic equivalent to risperidone for

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

Palonosetron

Section

Medicines for other common symptoms in palliative care

Antiemetic medicines

Indications

Therapeutic equivalent to ondansetron for

Palliative care

Therapeutic equivalent to ondansetron for

Nausea or vomiting

Pancreatic enzymes

Section

Pancreatic enzymes

Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.

Indications

Enzyme intestinal

Paracetamol (acetaminophen)

Section

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL

Local > Rectal > Suppository: 100 mg; 250 mg

Oral > Solid > dispersible tablet: 100 mg; 250 mg

Oral > Solid > tablet: 250 mg; 325 mg; 500 mg

Antimigraine medicines > For treatment of acute attack

Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL

Local > Rectal > Suppository: 250 mg

Oral > Solid > dispersible tablet: 100 mg; 250 mg

Oral > Solid > tablet: 250 mg; 325 mg; 500 mg

Indications

Pain

Migraine

Paromomycin

Section

Antileishmaniasis medicines

Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)

Antiamoebic and anti-giardiasis medicines

Oral > Liquid: 125 mg per 5 mL as sulfate

Oral > Solid: 250 mg as sulfate

Indications

Visceral leishmaniasis

Amoebiasis

Pegaspargase

Section

Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

Lymphoid leukaemia, not elsewhere classified

Pegfilgrastim

Section

Immunomodulators

Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

Indications

Acquired neutropaenia

Pegylated interferon alfa (2a)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C
Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications

Chronic hepatitis C

Pegylated interferon alfa (2b)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C
Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications

Chronic hepatitis C

Pembrolizumab

Section

Immunomodulators
Parenteral > General injections > IV: 50 mg powder for injection

Indications

Therapeutic equivalent to nivolumab for

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

Penicillamine

Section

Antidotes and other substances used in poisonings > Specific
Oral > Solid: 250 mg

Disease-modifying anti-rheumatic drugs (DMARDs)
Oral > Solid: 250 mg

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Rheumatoid arthritis, serology unspecified

Pentamidine

Section

Antileishmaniasis medicines
Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)

Medicines for the treatment of 1st stage African trypanosomiasis
Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection

Antipneumocystosis and antitoxoplasmosis medicines
Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)

Indications

Visceral leishmaniasis

African trypanosomiasis

Pneumocystosis

Permethrin

Section

Dermatological medicines > Scabicides and pediculicides

Local > Topical > Lotion: 1%

Local > Topical > Cream: 5%

Indications

Pediculosis corporis

Pediculosis capitis

Scabies

Pertussis vaccine

Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against pertussis alone

Pertuzumab

Section

Targeted therapies

Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution

Indications

Carcinoma of breast, specialised type

Phenelzine

Section

Medicines for depressive disorders

Oral > Solid > dosage form: 15 mg (as sulfate)

Indications

Other specified depressive disorders

Phenobarbital

Section

Antiseizure medicines

Oral > Liquid: 15 mg per 5 mL

Oral > Solid: 15 to 100 mg

Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)

Indications

Epilepsy or seizures

Status epilepticus

Phenoxymethylpenicillin

Section

Access group antibiotics

Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid

Oral > Solid: 250 mg (as potassium salt) tablet

Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

First choice

Acute pharyngitis

Periapical abscess without sinus

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Other indications

Bacterial infection of unspecified site

Phenytoin

Section

Antiseizure medicines

Oral > Liquid: 30 mg per 5 mL (phenytoin)

Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)

Oral > Solid > tablet: 50 mg (phenytoin) (chewable)

Oral > Solid > dosage form: 25 mg (phenytoin sodium); 50 mg (phenytoin sodium); 100 mg (phenytoin sodium)

Indications

Epilepsy or seizures

Phosphorus

Section

Medicines for endocrine disorders

Oral > Other: 500 mg in sachet (elemental phosphorus) granules

Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)

Indications

Hypophosphataemic rickets

Phytomenadione

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule

Oral > Solid: 10 mg tablet

Indications

Haemorrhagic disorder due to other specified circulating anticoagulants

Haemorrhagic or haematological disorders of fetus or newborn

Pilocarpine

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines
Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)

Indications

Acute angle closure with pupillary block

Ocular hypertension

Primary open-angle glaucoma

Piperacillin + tazobactam

Section

Watch group antibiotics
Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

First choice

Peritoneal abscess (severe)

Other specified pneumonia (Hospital-acquired pneumonia)

Neutropenia (high-risk)

Peritonitis (severe)

co-prescribed with clindamycin

Necrotising fasciitis

Platelets

Section

Blood and blood components
Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Plazomicin

Section

Reserve group antibiotics
Parenteral > General injections > IV: 500 mg per 10 mL

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Pneumococcal vaccine

Section

Recommendations for all immunization programmes
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against single bacterial diseases

Podophyllotoxin

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to podophyllum resin for

Anogenital warts

Therapeutic equivalent to podophyllum resin for

Plantar warts

Podophyllum resin

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Solution: 10 to 25%

Indications

Anogenital warts

Plantar warts

Poliomyelitis vaccine

Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against poliomyelitis

Polygeline

Section

Plasma substitutes

Parenteral > General injections > IV: 3.5% injectable solution

Parenteral > General injections > IV: 3.5% in solution

Indications

Therapeutic equivalent to dextran 70 for

Hypovolaemia

Hypovolaemia

Polymyxin B (injection)

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

Carbapenem resistant Acinetobacter baumannii

Carbapenem-resistant Pseudomonas aeruginosa

Carbapenem resistant Enterobacterales

Polymyxins

Section

Reserve group antibiotics

Indications

Other specified bacterial diseases

Potassium chloride

Section

Solutions correcting water, electrolyte and acid-base disturbances > Oral
Oral > Liquid: powder for solution

Solutions correcting water, electrolyte and acid-base disturbances >
Parenteral

Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K⁺ 1.5 mmol/mL and Cl⁻ 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K⁺ 1 mmol/mL and Cl⁻ 2 mmol/mL); 15% solution for dilution (equivalent to K⁺ 2 mmol/mL and Cl⁻ 2 mmol/mL)

Indications

Hypokalaemia

Hypokalaemia

Potassium ferric hexacyanoferrate (Prussian blue)

Section

Antidotes and other substances used in poisonings > Specific
Oral > Solid: Powder for oral administration

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Potassium iodide

Section

Antifungal medicines
Local > Topical > Solution: Saturated solution

Thyroid hormones and antithyroid medicines
Oral > Solid: 60 mg

Indications

Sporotrichosis

Thyrotoxicosis

Potassium permanganate

Section

Dermatological medicines > Anti-infective medicines
Local > Topical > Solution: aqueous solution: 1:10 000

Indications

Tropical phagedaenic ulcer

Pemphigus

Other specified pyogenic bacterial infection of skin and subcutaneous tissue

Impetigo

Povidone iodine

Section

Antiseptics
Local > Topical > Solution: 10% (equivalent to 1% available iodine)

Indications

Povidone iodine

Pralidoxime

Section

Antidotes and other substances used in poisonings > Specific

Indications

Exposure to or harmful effects of undetermined intent of pesticides

Pramipexole

Section

Antiseizure medicines

Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release

Indications

Parkinson disease

Pravastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to *simvastatin* for

Mixed hyperlipidaemia

Therapeutic equivalent to *simvastatin* for

Coronary atherosclerosis

Praziquantel

Section

Antischistosomes and other antitrematode medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

Paragonimiasis

Clonorchiasis

Opisthorchiasis

Schistosomiasis

Intestinal anthelmintics

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

Hymenolepiasis

Diphyllobothriasis

Cysticidal medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Cysticercosis of central nervous system

Precipitated sulfur

Section

Dermatological medicines > Scabicides and pediculicides

Local > Topical > Ointment:

Indications

Therapeutic equivalent to [benzyl benzoate](#) for

Pthiriasis

Therapeutic equivalent to [benzyl benzoate](#) for

Pediculosis corporis

Therapeutic equivalent to [benzyl benzoate](#) for

Pediculosis capitis

Therapeutic equivalent to [benzyl benzoate](#) for

Scabies

Prednisolone

Section

Hormones and antihormones

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

Anti-inflammatory medicines

Local > Rectal > Retention enema:

Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)

Antiallergics and medicines used in anaphylaxis

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

Ophthalmological preparations > Anti-inflammatory agents

Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Plasma cell myeloma

Follicular lymphoma

Lymphoid leukaemia, not elsewhere classified

Malignant neoplasms of prostate

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Hodgkin lymphoma

Diffuse large B-cell lymphomas

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Therapeutic equivalent to hydrocortisone for

Crohn disease site

Crohn disease site

Ulcerative colitis

Allergic or hypersensitivity conditions of unspecified type

Scleritis

Anterior uveitis

Prednisone

Section

Hormones and antihormones

Indications

Therapeutic equivalent to prednisolone for

Plasma cell myeloma

Therapeutic equivalent to prednisolone for

Follicular lymphoma

Therapeutic equivalent to prednisolone for

Lymphoid leukaemia, not elsewhere classified

Therapeutic equivalent to prednisolone for

Malignant neoplasms of prostate

Therapeutic equivalent to prednisolone for

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to prednisolone for

Hodgkin lymphoma

Therapeutic equivalent to prednisolone for

Diffuse large B-cell lymphomas

Therapeutic equivalent to prednisolone for

Anaplastic large cell lymphoma, ALK-negative

Therapeutic equivalent to prednisolone for

Anaplastic large cell lymphoma, ALK-positive

Therapeutic equivalent to prednisolone for

Langerhans cell histiocytosis

Antiallergics and medicines used in anaphylaxis

Therapeutic equivalent to prednisolone for

Allergic or hypersensitivity conditions of unspecified type

Pretomanid

Section

Antituberculosis medicines

Oral > Solid > tablet: 200 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Primaquine

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)

Indications

Malaria due to Plasmodium ovale

Malaria due to Plasmodium vivax

Probenecid

Section

Medicines used to treat gout

Oral > Solid: 500 mg

Indications

Gout

Procainamide

Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule (hydrochloride)

Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)

Indications

Cardiac arrhythmia

Procaine benzylpenicillin

Section

Access group antibiotics

Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

First choice

Congenital syphilis [children]

Second choice

Syphilis

Procarbazine

Section

Cytotoxic medicines

Oral > Solid: 50 mg (as hydrochloride)

Oral > Solid > capsule: 50 mg (as hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hodgkin lymphoma

Progesterone vaginal ring

Section

Intravaginal contraceptives

Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

Indications

Contact with health services for contraceptive management

Proguanil

Section

Antimalarial medicines > For chemoprevention

Oral > Solid: 100 mg tablet (hydrochloride)

Indications

Malaria due to Plasmodium falciparum

Promethazine

Section

Antiemetic medicines

Oral > Liquid: 5 mg per 5 mL (hydrochloride)

Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)

Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule

Indications

Nausea or vomiting

Propanol

Section

Antiseptics

Indications

Therapeutic equivalent to ethanol for

Denatured alcohol

Propofol

Section

General anaesthetics and oxygen > Injectable medicines

Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL

Indications

Anaesthetics and therapeutic gases

Propranolol

Section

Antihypertensive medicines

Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Antianginal medicines

Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)

Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Antiarrhythmic medicines

Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)

Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Antimigraine medicines > For prophylaxis

Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)

Indications

Essential hypertension

Angina pectoris

Cardiac arrhythmia

Migraine

Propylthiouracil

Section

Thyroid hormones and antithyroid medicines

Oral > Solid: 50 mg

Indications

Thyrotoxicosis

Prostaglandin E1

Section

Medicines administered to the neonate [c]
Parenteral > General injections > IV: 0.5 mg per mL in alcohol

Indications

Other specified congenital anomaly of great arteries including arterial duct

Prostaglandin E2

Section

Medicines administered to the neonate [c]
Parenteral > General injections > IV: 1 mg per mL

Indications

Therapeutic equivalent to [prostaglandin E1](#) for

Other specified congenital anomaly of great arteries including arterial duct

Other specified congenital anomaly of great arteries including arterial duct

Protamine sulfate

Section

Medicines affecting coagulation
Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule

Indications

Haemorrhagic disorder due to other specified circulating anticoagulants

Protionamide

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [ethionamide](#) for

Multi-drug resistant *Mycobacterium tuberculosis*

Pyrantel

Section

Intestinal anthelmintics
Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)

Indications

Ascariasis

Trichuriasis

Enterobiasis

Hookworm diseases

Pyrazinamide

Section

Antituberculosis medicines
Oral > Solid > dispersible tablet: 150 mg
Oral > Solid > tablet: 400 mg; 500 mg

Indications

Tuberculosis

Pyridostigmine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
Parenteral > General injections > IV: 1 mg in 1 mL ampoule
(pyridostigmine bromide)
Oral > Solid: 60 mg (pyridostigmine bromide)

Indications

Myasthenia gravis

Pyridoxine

Section

Vitamins and minerals
Oral > Solid: 25 mg (hydrochloride)

Indications

Vitamin B6 deficiency

Sideroblastic anaemia

Other specified polyneuropathy

Pyrimethamine

Section

Antipneumocystosis and antitoxoplasmosis medicines
Oral > Solid: 25 mg

Indications

Toxoplasmosis

Quetiapine

Section

Medicines for psychotic disorders

Medicines for bipolar disorders

Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)

Indications

Therapeutic equivalent to risperidone for

Schizophrenia or other primary psychotic disorders

Bipolar or related disorders

Quinidine

Section

Antiarrhythmic medicines
Oral > Solid: 200 mg (sulfate)

Indications

Cardiac arrhythmia

Quinine

Section

Antimalarial medicines > For curative treatment
Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)
Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)

Indications

Malaria due to *Plasmodium falciparum*

Rabies vaccine

Section

Recommendations for some high-risk populations
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against rabies

Raltegravir

Section

Antiretrovirals > Integrase inhibitors
Oral > Liquid: 100 mg granules for oral suspension
Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Ranibizumab

Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

Indications

Retinal venous occlusions

Diabetic macular oedema

Degenerative high myopia

Age related macular degeneration

Ranitidine

Section

Antiulcer medicines
Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
Oral > Solid: 150 mg (as hydrochloride)
Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)

Indications

Gastro-oesophageal reflux disease

Peptic ulcer, site unspecified

Rasburicase

Section

Supportive medicines

Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution

Indications

Tumour lysis syndrome

Ravidasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid > tablet: 200 mg

Indications

Chronic hepatitis C

Ready to use therapeutic food

Section

Therapeutic foods

Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines.

Indications

Acute malnutrition in infants, children or adolescents

Realgar-indigo naturalis formulation

Section

Cytotoxic medicines

Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Red blood cells

Section

Blood and blood components

Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Resin-based composite (high-viscosity)

Section

Dental medicines and preparations

Local > Topical > Other: Single-use capsule or multi-use syringe

Indications

Dental caries

Resin-based composite (low-viscosity)

Section

Dental medicines and preparations

Local > Topical > Other: Single-use applicator or multi-use bottle

Indications

Dental caries

Retinol

Section

Vitamins and minerals

Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection

Oral > Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser

Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule

Indications

Vitamin A deficiency

Ribavirin

Section

Other antivirals

Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution

Oral > Solid: 200 mg; 400 mg; 600 mg

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution

Oral > Solid: 200 mg; 400 mg; 600 mg

Indications

Viral haemorrhagic fever, not elsewhere classified

Chronic hepatitis C

Ribociclib

Section

Targeted therapies

Indications

Therapeutic equivalent to palbociclib for

Other specified malignant neoplasms of breast

Riboflavin

Section

Vitamins and minerals

Oral > Solid: 5 mg

Indications

Vitamin B2 deficiency

Rifabutin

Section

Antituberculosis medicines

Oral > Solid: 150 mg

Indications

Tuberculosis

Rifampicin

Section

Antituberculosis medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

Parenteral > General injections > IV: 600 mg in vial powder for injection

Antileprosy medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

Indications

Tuberculosis

Other specified tuberculosis

Leprosy

Rifapentine

Section

Antituberculosis medicines

Oral > Solid > tablet: 150 mg; 300 mg

Indications

Tuberculosis

Latent tuberculosis

Risdiplam

Section

Medicines for diseases of the nervous system

Oral > Liquid: 0.75 mg per mL powder for oral liquid

Indications

Spinal muscular atrophy

Risperidone

Section

Medicines for psychotic disorders

Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg

Parenteral > General injections > IM:

Indications

Schizophrenia or other primary psychotic disorders

Therapeutic equivalent to paliperidone for

Schizophrenia or other primary psychotic disorders

Ritonavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Rituximab

Section

Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Medicines for multiple sclerosis

Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial

Indications

Follicular lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphomas

Burkitt lymphoma including Burkitt leukaemia

Multiple sclerosis

Rivaroxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to dabigatran for

Venous thromboembolism

Therapeutic equivalent to dabigatran for

Other specified atrial fibrillation

Ropinirole

Section

Antiseizure medicines

Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 mg immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release

Indications

Parkinson disease

Rotavirus vaccine

Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Rubella vaccine

Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against rubella alone

Salbutamol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease
Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate)
Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler
Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers

Indications

Chronic obstructive pulmonary disease

Asthma

Salicylic acid

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation
Local > Topical > Solution: 5%

Indications

Seborrhoeic dermatitis

Psoriasis of unspecified type

Ichthyoses

Saquinavir

Section

Antiretrovirals > Protease inhibitors
Oral > Solid: 200 mg; 500 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Selenium sulfide

Section

Dermatological medicines > Antifungal medicines
Local > Topical > Suspension: 2% detergent-based

Indications

Seborrhoeic dermatitis

Pityriasis versicolor

Senna

Section

Medicines for other common symptoms in palliative care
Oral > Liquid: 7.5 mg per 5 mL oral liquid
Laxatives
Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)

Indications

Palliative care

Constipation

Sevoflurane

Section

General anaesthetics and oxygen > Inhalational medicines
Respiratory > Inhalation > liquid:

Indications

Anaesthetics and therapeutic gases

Silver diamine fluoride

Section

Dental medicines and preparations
Local > Dental > Solution: 38% w/v

Indications

Dental caries

Silver nitrate

Section

Ophthalmological preparations > Anti-infective agents
Local > Ophthalmological > Solution (eye drops): 1%

Indications

Neonatal conjunctivitis or dacryocystitis

Silver sulfadiazine

Section

Dermatological medicines > Anti-infective medicines
Local > Topical > Cream: 1%

Indications

Burns

Simeprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
Oral > Solid: 150 mg

Indications

Chronic hepatitis C

Simvastatin

Section

Lipid-lowering agents
Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg

Indications

Mixed hyperlipidaemia

Coronary atherosclerosis

Medicines for endocrine disorders

Oral > Solid: 20 mg

Polycystic ovary syndrome

Smallpox vaccine

Section

Recommendations for all immunization programmes
All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Snake antivenom

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium calcium edetate

Section

Antidotes and other substances used in poisonings > Specific
Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium chloride

Section

Solutions correcting water, electrolyte and acid-base disturbances >
Parenteral
Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na⁺ 154 mmol/L and Cl⁻ 154 mmol/L)

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Sodium hyaluronate

Section

Ophthalmological preparations

Indications

Therapeutic equivalent to hypromellose for

Keratoconjunctivitis sicca

Sodium hydrogen carbonate

Section

Solutions correcting water, electrolyte and acid-base disturbances >
Parenteral
Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na⁺ 167 mmol/L and HCO₃⁻ 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na⁺ 1000 mmol/L and HCO₃⁻ 1000 mmol/L)

Indications

Acidosis

Sodium nitrite

Section

Antidotes and other substances used in poisonings > Specific
Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium nitroprusside

Section

Antihypertensive medicines
Parenteral > General injections > IV: 50 mg in ampoule powder for infusion

Indications

Hypertensive crisis

Sodium stibogluconate

Section

Antileishmaniasis medicines
Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

Sodium thiosulfate

Section

Dermatological medicines > Antifungal medicines
Local > Topical > Solution: 15%

Antidotes and other substances used in poisonings > Specific
Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule

Indications

Pityriasis versicolor

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid > tablet: 200 mg; 400 mg

Indications

Chronic hepatitis C

Sofosbuvir + velpatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg

Indications

Chronic hepatitis C

Somatropin

Section

Medicines for endocrine disorders

Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge

Indications

Hypoglycaemia without associated diabetes

Spectinomycin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

Indications

Second choice

Gonococcal infection

Other indications

Bacterial infection of unspecified site

Spironolactone

Section

Medicines used in heart failure

Oral > Solid > tablet: 25 mg

Diuretics

Oral > Liquid: 5 mg per 5 mL; 10 mg per 5 mL; 25 mg per 5 mL

Oral > Solid > tablet: 25 mg

Indications

Heart failure

Oedema

Ascites

Stavudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 5 mg per 5 mL powder for oral solution

Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Streptokinase

Section

Thrombolytic medicines

Parenteral > General injections > IV: 1.5 million IU in vial powder for injection

Indications

Acute myocardial infarction

Streptomycin (injection)

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

Indications

Multi-drug resistant Mycobacterium tuberculosis

Succimer

Section

Antidotes and other substances used in poisonings > Specific

Oral > Solid: 100 mg

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sulfacetamide

Section

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Ointment: 10% (sodium salt)

Indications

Other specified conjunctivitis

Sulfadiazine

Section

Antipneumocystosis and antitoxoplasmosis medicines

Oral > Solid: 500 mg

Anti-infective medicines

Oral > Solid: 500 mg

Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)

Indications

Toxoplasmosis

Bacterial infection of unspecified site

Sulfadimidine

Section

Anti-infective medicines

Oral > Liquid: 500 mg per 5 mL

Oral > Solid: 500 mg

Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)

Indications

Bacterial infection of unspecified site

Sulfadoxine + pyrimethamine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 500 mg + 25 mg tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
Antimalarial medicines > For chemoprevention Oral > Solid: 500 mg + 25 mg tablet Oral > Solid: 250 mg + 12.5 mg tablet	Malaria due to Plasmodium falciparum Malaria

Sulfamethoxazole + trimethoprim

Section	Indications
Access group antibiotics Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet Oral > Solid > dispersible tablet: 100 mg + 20 mg	First choice Infectious cystitis Second choice Infectious gastroenteritis or colitis without specification of infectious agent Other indications Bacterial infection of unspecified site Pneumocystosis
Antipneumocystosis and antitoxoplasmosis medicines Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet Oral > Solid > dispersible tablet: 100 mg + 20 mg	

Sulfasalazine

Section	Indications
Disease-modifying anti-rheumatic drugs (DMARDs) Oral > Solid: 500 mg	Rheumatoid arthritis, serology unspecified
Anti-inflammatory medicines Oral > Solid: 500 mg Local > Rectal > Suppository: 500 mg Local > Rectal > Retention enema:	Crohn disease site Ulcerative colitis

Sumatriptan

Section

Antimigraine medicines > For treatment of acute attack
Oral > Solid: 50 mg

Indications

Migraine

Sunscreen (broad-spectrum)

Section

Dermatological medicines
Topical cream, lotion, gel, ointment, spray with sun protection factor \geq 50.

Indications

Albinism or other specified genetically-determined hypomelanotic disorders

Xeroderma pigmentosum

Suramin sodium

Section

Antifilarials
Parenteral > General injections > IV: 1 g in vial

Medicines for the treatment of 1st stage African trypanosomiasis
Parenteral > General injections > IV: 1 g in vial

Indications

Filariasis

African trypanosomiasis

Surfactant

Section

Medicines administered to the neonate [c]
Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation

Indications

Respiratory distress syndrome of newborn

Suxamethonium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial

Indications

Muscle relaxants

Tacalcitol

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to calcipotriol for

Psoriasis of unspecified type

Tacrolimus

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 5 mg per mL in 1 mL vial

Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension

Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)

Indications

Failure or rejection of transplanted organs or tissues

Tamoxifen

Section

Hormones and antihormones

Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Tedizolid

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to linezolid for

Methicillin resistant *Staphylococcus aureus*

Therapeutic equivalent to linezolid for

Vancomycin resistant *Staphylococcus aureus*

Therapeutic equivalent to linezolid for

Vancomycin resistant *Enterococcus*

Telmisartan + amlodipine

Section

Antihypertensive medicines

Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg

Indications

Essential hypertension

Telmisartan + hydrochlorothiazide

Section

Antihypertensive medicines

Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg

Indications

Essential hypertension

Tenofovir alafenamide

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 25 mg

Indications

Chronic hepatitis B

Tenofovir disoproxil fumarate

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Chronic hepatitis B

Terbinafine

Section

Dermatological medicines > Antifungal medicines
Local > Topical > Cream: 1% terbinafine hydrochloride
Local > Topical > Ointment: 1% terbinafine hydrochloride

Indications

Fungal infection of the skin

Terbutaline

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to salbutamol for

Chronic obstructive pulmonary disease

Therapeutic equivalent to salbutamol for

Asthma

Terizidone

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to cycloserine for

Multi-drug resistant Mycobacterium tuberculosis

Testosterone

Section

Androgens

Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)

Indications

Testicular dysfunction or testosterone-related disorders

Tetanus antitoxin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

Parenteral > General injections > IM: 50000 IU in vial

Indications

Tetanus

Tetanus vaccine

Section

Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against tetanus alone

Tetracaine

Section

Ophthalmological preparations > Local anaesthetics

Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)

Indications

Local anaesthetics

Tetracycline

Section

Access group antibiotics

Oral > Solid: 250 mg (hydrochloride)

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)

Indications

Bacterial infection of unspecified site

Neonatal conjunctivitis or dacryocystitis

Other specified conjunctivitis

Infectious keratitis

Infectious blepharitis

Trachoma

Thalidomide

Section

Immunomodulators

Oral > Solid: 50 mg

Indications

Plasma cell myeloma

Thiamine

Section

Vitamins and minerals

Oral > Solid: 50 mg (hydrochloride)

Indications

Vitamin B1 deficiency

Thiopental

Section

General anaesthetics and oxygen > Injectable medicines

Indications

Therapeutic equivalent to propofol for

Anaesthetics and therapeutic gases

Ticagrelor

Section

Anti-platelet medicines

Oral > Solid > tablet: 60 mg; 90 mg

Indications

Acute ischaemic heart disease

Presence of coronary angioplasty implant or graft

Tick-borne encephalitis vaccine

Section

Recommendations for certain regions

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against arthropod-borne viral encephalitis

Tigecycline

Section

Reserve group antibiotics

Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

Other specified bacterial diseases

Timolol

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)

Indications

Primary open-angle glaucoma

Ocular hypertension

Tinidazole

Section

Antiamoebic and anti giardiasis medicines

Indications

Therapeutic equivalent to metronidazole for

Amoebiasis

Tioguanine

Section

Cytotoxic medicines

Oral > Solid: 40 mg

Indications

Lymphoid leukaemia, not elsewhere classified

Tiotropium bromide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > dry powder: 18 µg capsule

Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation

Indications

Chronic obstructive pulmonary disease

Tisagenlecleucel

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to axicabtagene ciloleucel for

Diffuse large B-cell lymphomas

Tislelizumab

Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 10 mL

Indications

Malignant neoplasms of urinary tract

Hodgkin lymphoma

Other specified malignant neoplasms of bronchus or lung

Tobramycin

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to gentamicin for

Other specified conjunctivitis

Therapeutic equivalent to gentamicin for

Infectious blepharitis

Tocilizumab

Section

Medicines for juvenile joint diseases

Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial

Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe

Indications

Juvenile systemic arthritis

Tolbutamide

Section

Oral hypoglycaemic agents

Oral > Solid: 500 mg

Indications

Type 2 diabetes mellitus

Torsemide

Section

Medicines used in heart failure

Diuretics

Indications

Therapeutic equivalent to furosemide for

Heart failure

Therapeutic equivalent to furosemide for

Anuria or oliguria

Therapeutic equivalent to furosemide for

Oedema

Toripalimab

Section

Immunomodulators

Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

Malignant neoplasms of nasopharynx

Malignant neoplasms of oesophagus

Tramadol

Section

Opioid analgesics

Oral > Liquid: 100 mg per mL (hydrochloride)

Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release

Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride)

Indications

Chronic cancer pain

Trametinib

Section

Targeted therapies

Oral > Solid: 0.5 mg; 2 mg

Indications

Other specified melanoma of skin

Tranexamic acid

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Other medicines administered to the mother

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

Haemorrhage, not elsewhere classified

Postpartum haemorrhage

Trastuzumab

Section

Targeted therapies

Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

Trastuzumab emtansine

Section

Targeted therapies

Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

Triamcinolone hexacetonide

Section

Medicines for juvenile joint diseases

Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial

Indications

Juvenile idiopathic arthritis

Triclabendazole

Section

Antischistosomes and other antitrematode medicines

Oral > Solid > tablet: 250 mg (scored)

Indications

Paragonimiasis

Fascioliasis

Trihexyphenidyl

Section

Antiseizure medicines

Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)

Medicines for parkinsonism

Indications

Parkinson disease

Therapeutic equivalent to biperiden for

Parkinson disease

Trimethoprim

Section

Access group antibiotics

Oral > Liquid: 50 mg per mL

Oral > Solid: 100 mg; 200 mg

Indications

First choice

Infectious cystitis

Triptorelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to leuprorelin for

Malignant neoplasms of breast

Therapeutic equivalent to leuprorelin for

Malignant neoplasms of prostate

Tropicamide

Section

Diagnostic agents > Ophthalmic medicines

Local > Ophthalmological > Solution (eye drops): 0.5%

Indications

Cycloplegic drug

Tropisetron

Section

Medicines for other common symptoms in palliative care

Antiemetic medicines

Indications

Therapeutic equivalent to ondansetron for

Palliative care

Therapeutic equivalent to ondansetron for

Nausea or vomiting

Tuberculin, purified protein derivative

Section

Immunologicals > Diagnostic agents

Parenteral > Locoregional injections > Intradermal:

Indications

Mycobacterial diseases

Tubocurarine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride)

Indications

Muscle relaxants

Typhoid vaccine

Section

Recommendations for some high-risk populations

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against typhoid-paratyphoid alone

Ulipristal

Section

Oral hormonal contraceptives

Oral > Solid: 30 mg tablet (ulipristal acetate)

Indications

Contact with health services for postcoital contraception

Umeclidinium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to tiotropium bromide for

Chronic obstructive pulmonary disease

Urea

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Cream: 10%; 5%

Local > Topical > Ointment: 10%; 5%

Indications

Xerosis cutis or asteatosis

Ustekinumab

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 90 mg per mL in pre-filled syringe

Indications

Psoriasis of unspecified type

Valaciclovir

Section

Antiherpes medicines

Indications

Therapeutic equivalent to [aciclovir](#) for

Zoster

Therapeutic equivalent to [aciclovir](#) for

Varicella

Therapeutic equivalent to [aciclovir](#) for

Herpes simplex infections

Valganciclovir

Section

Other antivirals

Oral > Liquid: 50 mg per mL powder for oral solution

Oral > Solid > tablet: 450 mg

Indications

Cytomegaloviral retinitis

Valproic acid (sodium valproate)

Section

Antiseizure medicines

Oral > Liquid: 200 mg per 5 mL

Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule

Medicines for bipolar disorders

Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)

Indications

Epilepsy or seizures

Status epilepticus

Bipolar or related disorders

Vancomycin

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection

Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Indications

First choice

Necrotising fasciitis

co-prescribed with ceftazidime

Endophthalmitis

co-prescribed with ceftriaxone

Endophthalmitis

Second choice

Neutropenia (high-risk)

Intestinal infections due to *Clostridioides difficile*

Other indications

Methicillin resistant *Staphylococcus aureus*

Varenicline

Section

Medicines for nicotine use disorders

Oral > Solid: 0.5 mg; 1 mg

Indications

Nicotine dependence

Varicella vaccine

Section

Recommendations for immunization programmes with certain characteristics

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Vecuronium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
Parenteral > General injections > IV: 10 mg in vial powder for injection
(vecuronium bromide)

Indications

Muscle relaxants

Vemurafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to [dabrafenib](#) for

Other specified melanoma of skin

Verapamil

Section

Antiarrhythmic medicines
Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule
(hydrochloride)
Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

Antianginal medicines
Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

Indications

Supraventricular tachyarrhythmia

Angina pectoris

Vinblastine

Section

Cytotoxic medicines
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10
mg per 10 mL in vial (vinblastine sulfate)

Indications

Unspecified malignant neoplasms of ill-defined
or unspecified sites

Other specified gliomas of brain

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Other specified malignant neoplasms of the
ovary

Germ cell tumour of testis

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Langerhans cell histiocytosis

Vincristine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Kaposi sarcoma of unspecified primary site

Rhabdomyosarcoma primary site

Hodgkin lymphoma

Diffuse large B-cell lymphomas

Retinoblastoma

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Langerhans cell histiocytosis

Vinorelbine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial

Oral > Solid > capsule: 20 mg; 30 mg; 80 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of breast

Rhabdomyosarcoma primary site

Voriconazole

Section

Antifungal medicines

Parenteral > General injections > IV: 200 mg in vial powder for injection

Oral > Liquid: 40 mg per mL powder for oral liquid

Oral > Solid: 50 mg tablet; 200 mg tablet

Indications

Chronic pulmonary aspergillosis

Invasive aspergillosis

Warfarin

Section

Medicines affecting coagulation

Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)

Indications

Other specified diseases of arteries or arterioles

Cerebral ischaemic stroke due to embolic occlusion

Venous thromboembolism

Atrial fibrillation

Water for injection

Section

Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous

Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule

Indications

Unspecified appropriateness of dosing or administration without injury or harm

Whole blood

Section

Blood and blood components

Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Xylometazoline

Section

Ear, nose and throat medicines [c]

Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL

Indications

Nasal congestion

Yellow fever vaccine

Section

Recommendations for certain regions

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Zanubrutinib

Section

Targeted therapies

Oral > Solid: 80 mg

Indications

Mantle cell lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Zidovudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
Oral > Liquid: 50 mg per 5 mL
Oral > Solid > tablet: 300 mg
Oral > Solid > capsule: 250 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Zinc sulfate

Section

Medicines for diarrhoea
Oral > Solid: 20 mg

Indications

Diarrhoea

Zoledronic acid

Section

Supportive medicines
Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
Medicines for endocrine disorders
Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

Malignant neoplasm metastasis in bone or bone marrow

Osteogenesis imperfecta

Zuclopenthixol decanoate

Section

Medicines for psychotic disorders

Indications

Therapeutic equivalent to fluphenazine for

Schizophrenia or other primary psychotic disorders